If you survived Covid-19, donate blood for Vaccine research.

THE CORONA COVID-19 DISEASE WITH THE SARS-CoV-2 VIRUS.

What I understand so far...
1. It is a powerful and deadly virus for people with weak immune systems.
2. People over Seventy years of age are the most vulnerable.
3. A medical respirator is a necessary life-saver for those infected by the virus.
4. Every hospital in Canada may need a minimum of five hundred medical respirators and they should be prioritized by the Canadian government and then quickly manufactured and dispensed throughout Canada before the virus expands into the general population.
5. The steps we as individuals need to take include refraining from joining groups over Ten people and also, cleaning our hands with a strong hand soap. Look at the bottom of this page for a cheap but powerful hand cleanser.
6. If you must go to a shopping center for groceries, wear gloves. If there are registered cases of the virus in your area, I suggest wearing a surgical mask if available but if not, a construction mask may be the next best thing.
7. If possible, get yourself tested for the virus and if a medical authority quarantines you, obey without question.
8. If you have recovered from the SARS-CoV-2 virus and you feel strong enough, donate a litre of your blood. Somewhere around the world a smart scientist may use your plasma to create a Vaccine against Covid-19.
I will visit a laboratory to understand more about the Covid-19 disease containing the SARS-CoV-2 virus which causes the disease, then I will report back.
Good luck!
Signed: N.J. Raglione.

Hello Gentle People. Here is more information on the Covid-19 epidemic.
" Research shows that the SARS-CoV-2 virus causing the COVID-19 DISEASE EPIDEMIC is spread through close contact with an infected person and it is most contagious before and during the first week of symptoms.
Infection can occur in two ways, droplet and contact.
Droplets' mean respiratory droplets produced by an infected person's sneeze or cough. These can travel up to 6 feet or (1.8 meters). A person becomes infected when droplets from a cough or sneeze directly enter the body through the eyes, mouth, or nose.
Contact means touching a person directly or object directly, such as door handles that have droplets on them from an infected person's cough or sneeze. Unwashed hands contaminated with COVID-19 can introduce the virus to your body when you touch your eyes, mouth or nose. Washing your hands often and avoiding touching your face are two very important ways to help prevent the spread of COVID-19"
SUNNYBROOK...HEALTH SCIENCES CENTRE.
=======
Hello again!
Here is a quick and easy way to disinfect your hands. Fill a plastic pump bottle with Vinegar and squirt in some dish soap. Except for the pump bottle which you can buy at any Dollar store, the Vinegar and dish soap are handy kitchen products usually found in most homes. You will be surprised how well this works not only cleaning your hands but your dishes and almost anything you want to keep clean around the house...and it is cheap to make.
Now for some potential life saving good news! During the early stage of the disease, you can strengthen your body and help your lungs fight the infection by taking Vitamin B3 tablets and also by eating foods containing B3. They won't cure the infection but might help save your energy and keep you alive during your immune system's fight against the SARScoV2. 
What foods are high in b3? Good sources of vitamin B3, also known as Niacin, include yeast, meat, poultry, redfish (e.g., tuna, salmon), cereals, legumes, and seeds. Milk, green leafy vegetables, coffee, and tea also provide some niacin.
Don't forget to call an ambulance if the disease climbs up to level 2 and things get rough!

Keep clean and good luck in your struggle against the Covid-19 epidemic. N.J. Raglione. Dir. The World Friendly Peace and Ecology Movement.
----------------------------
POTENTIAL CURES FOR COVID-19
-----------------------------------------------
THE SHORT VERSION: REPURPOSING DRUGS.
Three existing anti-virus drugs may have a chance against the Covid-19 virus. They are:
1. REMDESIVIR... A viral inhibitor. It seems to be the best so far and is undergoing testing in China.
2. ACE2... A human protein inhibitor which may decoy the Covid virus by glomming on to the virus and preventing it from getting into cells. Adding extra ACE2 may help protect the existing ACE2 in protecting the cells which cover the lungs.
3. CHLOROQUINE...It is an anti-malaria drug that inhibits the ability of the new virus to infect and grow in Monkey cells. Combining Chloroquine with Remdesivir is also under testing in China.
4. The H.I.V. drug Kaletra, also called Aluvia, is a combination of two Protease inhibitors: Lopinavir and Ritonavir. Kaletra is being tested in China.
5. High doses of Lopinavir combined with Ritonavir worked to cure a 70-year-old lady in Bankok.

=================================================================
THE PRECISE VERSION:
"Repurposed drugs may help scientists fight the new coronavirus.
Work on similar viruses is giving researchers clues to develop drugs against the disease.
A patient who recovered from COVID-19 is discharged from a Wuhan hospital on February 18. His plasma may help to create a vaccine against the Coronavirus: Covid-19.

STR/AFP/GETTY IMAGES

Share this on:
Facebook
Twitter
Pocket
Reddit
Print
By Tina Hesman Saey

MARCH 10, 2020 AT 7:00 AM

As the new coronavirus makes its way around the world, doctors and researchers are searching for drugs to treat the ill and stop the spread of the disease, which has already killed more than 3,800 people since its introduction in Wuhan, China, in December.

The culprit virus is in the same family as the coronaviruses that caused two other outbreaks, severe acute respiratory syndrome, and the Middle East respiratory syndrome. But the new coronavirus may be more infectious. In early March, the number of confirmed cases of the new disease, called COVID-19, had exceeded 100,000, far surpassing the more than 10,600 combined total cases of SARS and MERS.

Health officials are mainly relying on quarantines to try to contain the virus’ spread. Such low-tech public health measures were effective at stopping SARS in 2004, Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, said January 29 in Arlington, Va., at the annual American Society for Microbiology’s Biothreats meeting.

But stopping the new virus may require a more aggressive approach. In China alone, about 300 clinical trials are in the works to treat sick patients with standard antiviral therapies, such as interferons, as well as stem cells, traditional Chinese medicines including acupuncture, and blood plasma from people who have already recovered from the virus.

Sign Up For the Latest from SCIENCE NEWS.
Headlines and summaries of the latest Science News articles can be delivered to your inbox

E-mail*
human4usbillions@gmail.com
GO
Researchers are not stopping there. They also are working to develop drugs to treat infections and vaccines to prevent them (SN: 3/14/20, p. 6). But creating therapies against new diseases often takes years, if not decades. With this new coronavirus, now known as SARS-CoV-2, nobody wants to wait that long. Thanks to their experience developing treatments against the MERS coronavirus, as well as other diseases, such as HIV, hepatitis C, influenza, Ebola and malaria, researchers are moving quickly to see what they can borrow to help patients sooner.

“Repurposing drugs is absolutely the best thing that could happen right now.”

Karla Satchell, Northwestern University Feinberg School of Medicine
Finding new uses for old drugs is a good strategy, especially when racing to fight a fast-moving disease for which there is no treatment, says Karla Satchell, a microbiologist, an immunologist at Northwestern University Feinberg School of Medicine in Chicago.

“Repurposing drugs is absolutely the best thing that could happen right now,” Satchell says. Potentially, drugs that combat HIV or hepatitis C might be able to put the new coronavirus in check, too. “Those drugs exist. They’ve been produced. They’ve been tested in patients,” she says. Although these drugs aren’t approved to treat the new coronavirus disease, they’re a great place to start. One of the most promising candidates, however, hasn’t yet been approved for any disease.

Early focus
Scientists have been quick to reveal the new corona­virus’ secrets. When SARS emerged in 2002, researchers took about five months to get a complete picture of the virus’s genetic makeup, or genome. With the new virus, Chinese health officials first reported a cluster of mysterious pneumonia cases in Wuhan to the World Health Organization on December 31. By January 10, the new coronavirus’s full genome was made available to researchers worldwide in public databases.

A virus’s genome is one of the most valuable tools scientists have for understanding where the pathogen came from, how it works and how to fight it. The first thing that coronaviruses have in common is that their genetic material is RNA, a chemical cousin to DNA.

Researchers immediately began comparing the new coronavirus’s genome with SARS and MERS viruses and other RNA viruses to determine whether drugs developed to combat those disease-­causing organisms would work against the new threat. As a result, some potential Achilles’ heels of SARS-CoV-2 have already come to light.

One target is the virus’s main protein-cutting enzyme, called M protease. RNA viruses often make one long string of proteins that later get cut into individual proteins to form various parts of the virus. In the new coronavirus, the M protease is one of 16 proteins that are linked like beads on a string, says Stephen Burley, an oncologist and structural biologist at Rutgers University in Piscataway, N.J.


DAVID S. GOODSELL/RCSB PROTEIN DATA BANK
M protease (model is shown) is a key enzyme for the new corona­virus’ survival and may be an Achilles’ heel. Drugs (blue) might be able to nestle into the enzyme and stop viral replication.
The virus can mature and infect new cells only if M protease can snip the string of proteins free, he says. Stop the protease from cutting and the virus can’t reproduce or replicate.

Existing drugs might be able to stop the virus’s M protease, two research groups proposed online January 29 at bioRxiv.org. One group suggested four drugs, including one used to treat hepatitis C and two aimed at HIV. A second group named 10 candidates, including an anti-nausea medication, an antifungal drug, and some cancer-fighting drugs.

HIV and hepatitis C are both RNA viruses that need a protease to cut proteins free from long chains. Drugs that inhibit those proteases can reduce levels of HIV and hepatitis C viruses to undetectable. Some of those drugs are now being tested against the new coronavirus in clinical trials in China.

The HIV drug Kaletra, also called Aluvia, is a combination of two protease inhibitors, lopinavir, and ritonavir. Kaletra’s maker, the global pharmaceutical company AbbVie, announced on January 26 that it is donating the drug to be tested in COVID-19 patients in China. Kaletra will be tested alone or in combination with other drugs. For instance, researchers may combine Kaletra with Arbidol, a drug that prevents some viruses from fusing with and infecting human cells. Arbidol may be tested on its own as well.

See all our coverage of the 2019 novel coronavirus outbreak
But the HIV drugs may not work against the new virus because of two differences in the proteases. The coronavirus protease cuts proteins in different spots than does the HIV protease say: Guangdi Li of the Xiangya School of Public Health of Central South University in Changsha, China, and Erik De Clercq, a pioneer in HIV therapy at KU Leuven in Belgium. Secondly, the HIV drugs were designed to fit a pocket in HIV’s protease that doesn’t exist in the new coronavirus’s protease, the researchers reported February 10 in Nature Reviews Drug Discovery.

Yet a few anecdotal accounts suggest the HIV drugs may help people with COVID-19 recover. Doctors at Rajavithi Hospital in Bangkok reported in a news briefing February 2 that they had treated a severely ill 70-year-old woman with high doses of a combination of lopinavir and ritonavir and the anti-influenza drug oseltamivir, which is sold as Tamiflu. Within 48 hours of treatment, the woman tested negative for the virus.

Her recovery may be due more to the HIV drugs than to oseltamivir. In 124 patients treated with oseltamivir at Zhongnan Hospital of Wuhan University, “no effective outcomes were observed,” doctors reported on February 7 in JAMA. Clinical trials in which these drugs are given to more people in carefully controlled conditions are needed to determine what to make of those isolated reports.

Viral weak spots
Researchers may be able to exploit a second weakness in the virus: its copying process, specifically the enzymes known as RNA-dependent RNA polymerases that the virus uses to make copies of its RNA. “Those enzymes are absolutely essential,” says Mark Denison, an evolutionary biologist at Vanderbilt University School of Medicine in Nashville. If the enzyme doesn’t work, “you can’t make new virus.”

Denison and colleagues have been testing molecules that muck with the copying machinery of RNA viruses. The molecules mimic the nucleotides that RNA polymerases string together to make viral genomes. Researchers have tested chemically altered versions of two RNA nucleotides — adenosine and cytidine — against a wide variety of RNA viruses in test tubes and in animals. The molecules “get incorporated into the viral RNA and either stop it from growing or they damage it by introducing mutations,” Denison says.

One of the molecules that researchers are most excited about is an experimental drug called Remdesivir. The drug is being tested in people with COVID-19 because it can stop the MERS virus in the lab and in animal studies. The drug has also been used in patients with Ebola, another RNA virus.

Remdesivir has been given to hundreds of people infected with Ebola, without causing serious side effects, but the drug hasn’t been as effective as scientists had hoped, virologist Timothy Sheahan of the University of North Carolina at Chapel Hill said January 29 at the Biothreats meeting. In a clinical trial in Congo, for example, about 53 percent of Ebola patients treated with remdesivir died, researchers reported November 27 in the New England Journal of Medicine. That’s better than the 66 percent of infected people killed in the ongoing Ebola outbreak, but other drugs in the trial were more effective.

Repurposed drugs that might treat COVID-19
Several drugs are in testing to target various parts of the new coronavirus.

Remdesivir
Designed to treat: RNA viruses (MERS, Ebola)
Evidence for: Lab tests against the COVID-19 virus; animal tests against MERS; tests in people with Ebola
Evidence against: Not as helpful as other drugs against Ebola
Lopinavir/ritonavir
Designed to treat: HIV
Evidence for: HIV and the new virus have a similar enzyme; anecdotal evidence in COVID-19 patients
Evidence against: The enzymes work differently; the new virus doesn’t have the pocket that the HIV drugs fit into to block the enzyme
Chloroquine
Designed to treat: Malaria
Evidence for: Lab tests against COVID-19
Evidence against: No data
APN01 (ACE2 protein decoy)
Designed to treat: SARS
Evidence for: Tests in animals infected with other viruses; tests in people with lung damage
Evidence against: It didn’t completely protect people with acute respiratory distress syndrome
Several tests of Remdesivir in lab animals infected with MERS have researchers still hopeful when it comes to the new coronavirus. In studies in both rhesus macaques and mice, Remdesivir protected animals from lung damage whether the drug was given before or after infection. Molecular pathologist Emmie de Wit of NIAID’s Laboratory of Virology in Hamilton, Mont., and colleagues reported the monkey results February 13 in the Proceedings of the National Academy of Sciences.

“Remdesivir appears to be one of the most promising antiviral treatments tested in a nonhuman primate model to date,” the team wrote. The results also suggest Remdesivir given before infection might help protect health care workers and family members of infected people from getting severe forms of the disease, Sheahan says.

Denison, Sheahan, and colleagues tested Remdesivir on infected human lung cells in the lab and in mice infected with MERS. Remdesivir was more potent at stopping the MERS virus than HIV drugs and interferon-beta, the researchers reported January 10 in Nature Communications.

But the question is still open about whether Remdesivir can stop the new coronavirus.

In lab tests, it can. Both Remdesivir and the antimalaria drug chloroquine inhibited the new virus’s ability to infect and grow in monkey cells, virologist Manli Wang of the Wuhan Institute of Virology of the Chinese Academy of Sciences and colleagues reported February 4 in Cell Research. Remdesivir also stopped the virus from growing in human cells. Chloroquine can block infections by interfering with the ability of some viruses — including coronaviruses — to enter cells. Wang and colleagues found that the drug could also limit growth of the new coronavirus if given after entry. Chloroquine also may help the immune system fight the virus without the kind of over­reaction that can lead to organ failure, the researchers propose.

In China, Remdesivir is already being tested in patients. And NIAID announced February 25 that it had launched a clinical trial of Remdesivir at the University of Nebraska Medical Center in Omaha. The first enrolled patient was an American evacuated from the Diamond Princess cruise ship in Japan that had been quarantined in February because of a COVID-19 outbreak.

Ultimately, nearly 400 sick people at 50 centers around the world will participate in the NIAID trial, which will compare "Remdesivir" with a placebo. The trial may be stopped or altered to add other drugs depending on results from the first 100 or so patients, says Andre Kalil, an infectious disease physician at the University of Nebraska Medical Center.

Researchers considered many potential therapies, but based on results from the animal and lab studies, “remdesivir seemed to be the one that was more promising,” Kalil says.

man donating plasma
This man in Wuhan, China, recovered from COVID-19 and is donating plasma for critically ill patients. The plasma contains antibodies that may fight the virus.
BARCROFT MEDIA/GETTY IMAGES
In the early patient studies, figuring out when to give Remdesivir to patients might not be easy, Sheahan says. Often drugs are tested on the sickest patients. For example, those in the NIAID trial must have pneumonia to participate. By the time someone lands in the intensive care unit with COVID-19, it may be too late for Remdesivir to combat the virus, Sheahan says. It may turn out that the drug works best earlier in the disease, before viral replication peaks.

“We don’t know because it hasn’t really been evaluated in people how Remdesivir will work, or if it will work at all,” Sheahan cautions.

The drug seems to have helped a 35-year-old man in Snohomish County, Wash., researchers reported January 31 in the New England Journal of Medicine. The man had the first confirmed case of COVID-19 in the United States. He developed pneumonia, and doctors treated him with intravenous Remdesivir. By the next day, he was feeling better and was taken off supplemental oxygen.

That’s just one case, and the company that makes Remdesivir has urged caution. “Remdesivir is not yet licensed or approved anywhere globally and has not been demonstrated to be safe or effective for any use,” the drug’s maker, biopharmaceutical company Gilead Sciences, headquartered in Foster City, Calif., said in a statement on January 31.

Too many trials of less-promising candidates are being offered. “We have got to start prioritizing enrollment into those things that may save lives and save them faster.”

Bruce Aylward, WHO assistant director-general
But global health officials are eager to see the drug tested in people. “There’s only one drug right now that we think may have real efficacy, and that’s remdesivir,” WHO’s assistant director-general Bruce Aylward said during a news briefing on February 24. But researchers in China are having trouble recruiting patients into remdesivir studies, partly because the number of cases has been waning and partly because too many trials of less-promising candidates are being offered. “We have got to start prioritizing enrollment into those things that may save lives and save them faster,” Aylward said.

Decoy defense
Another strategy for combating COVID-19 involves distracting the virus with decoys. Like the SARS virus, the new virus enters human cells by latching on to a protein called ACE2. The protein studs the surface of cells in the lungs and many other organs. A protein on the surface of the new virus binds to ACE2 10 to 20 times as tightly as the SARS protein does.

Researchers at Vienna-based Apeiron Biologics announced February 26 that they would use human ACE2 protein in a clinical trial against the new coronavirus. When released into the body, the extra ACE2 acts as a decoy, glomming on to the virus, preventing it from getting into cells.

ACE2 isn’t just a virus’s doorway to infection. Normally, it helps protect the lungs against damage, says Josef Penninger, an immunologist at the University of British Columbia in Vancouver and a cofounder of Apeiron. Penninger and colleagues reported the protein’s protective qualities, based on studies with mice, in Nature in 2005.

During a viral infection, the protein is drawn away from the cell surface and can’t offer protection. Penninger thinks that adding in extra ACE2 may help shield the lungs from damage caused by the virus and by immune system overreactions. The protein is also made in many other organs. Penninger and colleagues are testing whether the new virus can enter other tissues, which might be how the virus leads to multiple organ failures in severely ill people.

The decoy protein drug, called APN01, has already been through Phase I and Phase II clinical testing. “We know it’s safe,” Penninger says. Now researchers just need to determine whether it works.

Persistent problem solving
No one knows whether any of these approaches can help stem the spread of COVID-19.

“Right now, we need lots of people working with lots of ideas.”

Karla Satchell
“Right now, we need lots of people working with lots of ideas,” Satchell says. Similarities between the viruses that cause SARS and COVID-19 may mean that some drugs could work against both. “There is a hope that several small molecules that were identified as inhibitors of the SARS protease would represent reasonable starting points for trying to make a drug for the 2019 coronavirus,” Burley says.

“The open question is, can you produce a drug that is both safe and effective quickly enough to have an impact?” SARS was stopped by traditional infection-control measures in 2004, before any virus-fighting drugs made it through the development pipeline.

But had a decision been made then to spend $1 billion to make a safe and effective drug against SARS, Burley says, such a drug might be working now against the new coronavirus, eliminating the need to spend hundreds of billions of dollars to contain this new infection.

An investment in SARS would not have paid off for people with MERS, which is still a danger in the Middle East. The MERS virus is too different from SARS at the RNA level for SARS drugs to work against it.

But a future coronavirus might emerge that is similar enough to SARS and SARS-CoV-2 to be worth the cost, Burley says. Even if the current outbreak dwindles and disappears, he says, governments and companies should keep investing in drugs that can stop coronaviruses.

“I’m quite certain that the economic impact of the epidemic is going to run into the hundreds of billions,” he says. “So you would only need a 1 percent chance of something that was treatable with the drug to show up in the future to have made a good investment.”


Trustworthy journalism comes at a price.
Scientists and journalists share a core belief in questioning, observing and verifying to reach the truth. Science News reports on crucial research and discovery across science disciplines. We need your financial support to make it happen – every contribution makes a difference.

SUPPORT SCIENCE NEWS
Questions or comments on this article? E-mail us at feedback@sciencenews.org

CITATIONS
AbbVie Inc. AbbVie Statement on Coronavirus and lopinavir/ritonavir. January 27, 2020.

World Health Organization. Global research on coronavirus disease (COVID-19).

Y. Li et al. Therapeutic drugs targeting 2019-nCoV main protease by high-throughput screening. bioRxiv.org. January 29, 2020. doi:10.1101/2020.01.28.922922.

X. Liu and X.-J. Wang. Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines. bioRxiv.org. January 29, 2020. doi:10.1101/2020.01.29.924100

A. Wu et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host & Microbe. Published online February 7, 2020. doi:10.1016/j.chom.2020.02.001

S. Mulangu et al. A randomized, controlled trial of Ebola virus disease therapeutics. New England Journal of Medicine. Published on November 27, 2019. doi: 10.1056/NEJMoa1910993

T.P. Sheahan et al. Comparative therapeutic efficacy of Remdesivir and combination lopinavir, ritonavir, and Interferon-beta against MERS-CoV. Nature Communications. Published online January 10, 2020. doi:10.1038/s41467-019-13940-6.

M. Wang et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Reports. Published online February 4, 2020. doi:10.1038/s41422-020-0282-0.

E. de Wit et al. Prophylactic and therapeutic Remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proceedings of the National Academy of Sciences. Published online February 13, 2020. doi:10.1073/pnas.1922083117.

Gilead Sciences. Gilead Sciences' statement on the company’s ongoing response to the 2019 novel coronavirus (2019-nCoV). January 31, 2020.

M.L. Holshue et al. First case of 2019 novel coronavirus in the United States. New England Journal of Medicine. Published online January 31, 2020. doi:10.1056/NEJMoa2001191.

D. Wang et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. Published online February 7, 2020. doi:10.1001/jama.2020.1585.

G. Li and E. de Clercq. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery. Published online February 10, 2020. doi:10.1038/d41573-020-00016-0.

Y. Imai et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. Vol. 436, July 7, 2005, p. 112. doi: 10.1038/nature03712

Tina Hesman Saey
About Tina Hesman Saey
E-mail
Twitter
Tina Hesman Saey is the senior staff writer and reports on molecular biology. She has a Ph.D. in molecular genetics from Washington University in St. Louis and a master’s degree in science journalism from Boston University.

Related Stories
A woman who may have 2019-nCoV
HEALTH & MEDICINE
Your most pressing questions about the new Coronavirus answered
By Science News StaffJanuary 29, 2020
vet holding a dog
HEALTH & MEDICINE
A dog in Hong Kong has a low-level infection of the new coronavirus
By Erin Garcia de JesusMarch 5, 2020
2019-nCoV transmission electron micrograph
HEALTH & MEDICINE
How the new coronavirus stacks up against SARS and MERS
By Tina Hesman SaeyJanuary 24, 2020
More Stories from Science News on Health & Medicine


hydroxyapatite and amelotin deposits
HEALTH & MEDICINE
A tooth-enamel protein is found in eyes with a common form of macular degeneration
By Alex Fox4 hours ago
Wuhan Red Cross Hospital
HEALTH & MEDICINE
Why some heart patients may be especially vulnerable to COVID-19
By Aimee CunninghamMarch 20, 2020
young adults at Pompano Beach
HEALTH & MEDICINE
Young adults can face severe cases of COVID-19, too
By Erin Garcia de JesusMarch 19, 2020

HEALTH & MEDICINE
HIV drugs didn’t work as a coronavirus treatment in a clinical trial
By Tina Hesman SaeyMarch 19, 2020
kids washing their hands
HEALTH & MEDICINE
How parents and kids can stay safe and sane during the coronavirus pandemic
By Laura SandersMarch 19, 2020
Multimammate rats
HEALTH & MEDICINE
50 years ago, scientists were trying to get a grip on Lassa fever
By Cassie MartinMarch 19, 2020
Pedestrians in Wuhan
HEALTH & MEDICINE
People who didn’t know they had COVID-19 drove its spread in China
By Aimee CunninghamMarch 17, 2020
microscope image of a coronavirus
HEALTH & MEDICINE
Coronavirus is most contagious before and during the first week of symptoms
By Tina Hesman SaeyMarch 13, 2020
Items 1 through 1 of 8
From the Nature IndexPAID CONTENT
Science News
Science News was founded in 1921 as an independent, nonprofit source of accurate information on the latest news of science, medicine, and technology. Today, our mission remains the same: to empower people to evaluate the news and the world around them. It is published by the Society for Science & the Public, a nonprofit 501(c)(3) membership organization dedicated to public engagement in scientific research and education.

Science News for Students
Science News in High Schools
SUBSCRIBER SERVICES
Subscribe
Renew
Give a Gift Subscription
Follow Science News on Facebook
Follow Science News on Twitter
Follow Science News via RSS
Follow Science News on Instagram
MORE INFORMATION
FAQ
Rights & Permissions
Advertise
SOCIETY FOR SCIENCE & THE PUBLIC
About the Society
Donate
Careers
© Society for Science & the Public 2000–2020. All rights reserved.

1719 N Street, N.W., Washington, D.C. 20036
202.785.2255
Terms of Service Privacy Policy


Pilot clinical trial in China to test UBC researcher’s findings as a targeted therapy for COVID-19
February 25, 2020
APN01 — a drug made by Apeiron Biologics and developed based on the work of UBC’s Josef Penninger — already shown to block viral spread in SARS
A UBC Faculty of Medicine researcher is part of an international team working with a biotechnology company on a pilot clinical trial of a potential new treatment for patients with severe coronavirus infections in China.

Dr. Josef Penninger, director of UBC’s Life Sciences Institute and Canada 150 Chair in Functional Genetics, is working closely with Vienna-based APEIRON Biologics AG on a randomized, dual-arm trial that will treat 24 patients for seven days to determine whether APN01 treatment improves outcomes in patients with severe SARS-CoV-2 infection, the virus that causes COVID-19 disease.

APN01, a drug candidate of APEIRON, is based on previous work in the early 2000s, when Penninger, together with Drs. Arthur Slutsky (University of Toronto) and Chengyu Jiang (Peking Medical Union College), discovered that a protein called ACE2 was the critical receptor for the SARS virus and also protected the lung.


Dr. Josef Penninger

“As a result of SARS revealing its secrets of how it damages the lung, it has also shown us how to develop new medicines to treat other diseases,” says Penninger, a professor in the department of medical genetics. “Now, it turns out that the SARS-CoV-2 virus also uses ACE2 to infect cells. So ACE2 is the rational and targeted therapy for the new epidemic. First, APN01 keeps the virus from infecting cells, and second, it should prevent lung failure and multiple organ complications, the source of most of the mortality we are seeing with COVID-19.”

During the trial, which will begin shortly in China, researchers will assess participants to determine if APN01 reduces the viral load of SARS-CoV-2 virus, as well as the number of days patients endure fever. Data from the trial will be evaluated to determine if there is a need for an additional clinical trial in a larger number of patients.

An international team of Canadian, Chinese, and European experts, including Penninger, co-founder of APEIRON and the APEIRON team, Dr. Liqun Zhang and team of Angalpharma Co., Ltd (Suzhou, China), are coordinating the Chinese clinical trial with the support of dMed Pharmaceutical Co., a CRO team based in China. Drs. Haibo Zhang and Arthur Slutsky at St. Michaels Hospital in Toronto will determine if APN01 improves severe disease of the new coronavirus outbreak.

The trial in China is being led by Dr. Yimin Li, the ICU director who fought the 2003 SARS outbreak Guangdong Province, and Dr. Nanshan Zhong, the Chair of the National COVID-19 Commission in China.

Contact Information
Communications
UBC Faculty of Medicine
Email: communications.med@ubc.ca
Office: 604.822.2421

MUST READ: The Complete History Of Monsanto — “The World's Most Evil Corporation”
WEDNESDAY, SEPTEMBER 9, 2015
Shared from Facebook.▼
Of all the mega-corps running amok, Monsanto has consistently outperformed its rivals, earning the crown as “most evil corporation on Earth!” Not content to simply rest upon its throne of destruction, it remains focused on newer, more scientifically innovative ways to harm the planet and its people. 1901: The company is founded by John Francis Queeny, a member of the Knights of Malta, a thirty year pharmaceutical veteran married to Olga Mendez Monsanto, for which Monsanto Chemical Works is named. The company's first product is chemical saccharin, sold to Coca-Cola as an artificial sweetener. Even then, the government knew saccharin was poisonous and sued to stop its manufacture but lost in court, thus opening the Monsanto Pandora's Box to begin poisoning the world through the soft drink. 1920s: Monsanto expands into industrial chemicals and drugs, becoming the world's largest maker of aspirin, acetylsalicyclic acid, (toxic of course). This is also the time when things began to go horribly wrong for the planet in a hurry with the introduction of their polychlorinated biphenyls (PCBs). “PCBs were considered an industrial wonder chemical, an oil that wouldn't burn, impervious to degradation and had almost limitless applications. Today PCBs are considered one of the gravest chemical threats on the planet. Widely used as lubricants, hydraulic fluids, cutting oils, waterproof coatings and liquid sealants, are potent carcinogens and have been implicated in reproductive, developmental and immune system disorders. The world's center of PCB manufacturing was Monsanto's plant on the outskirts of East St. Louis, Illinois, which has the highest rate of fetal death and immature births in the state.”(1) Even though PCBs were eventually banned after fifty years for causing such devastation, it is still present in just about all animal and human blood and tissue cells across the globe. Documents introduced in court later showed Monsanto was fully aware of the deadly effects, but criminally hid them from the public to keep the PCB gravy-train going full speed! 1930s: Created its first hybrid seed corn and expands into detergents, soaps, industrial cleaning products, synthetic rubbers and plastics. Oh yes, all toxic of course! 1940s: They begin research on uranium to be used for the Manhattan Project's first atomic bomb, which would later be dropped on Hiroshima and Nagasaki, killing hundreds of thousands of Japanese, Korean and US Military servicemen and poisoning millions more. The company continues its unabated killing spree by creating pesticides for agriculture containing deadly dioxin, which poisons the food and water supplies. It was later discovered Monsanto failed to disclose that dioxin was used in a wide range of their products because doing so would force them to acknowledge that it had created an environmental Hell on Earth. 1950s: Closely aligned with The Walt Disney Company, Monsanto creates several attractions at Disney's Tomorrowland, espousing the glories of chemicals and plastics. Their “House of the Future” is constructed entirely of toxic plastic that is not biodegradable as they had asserted. What, Monsanto lied? I'm shocked! “After attracting a total of 20 million visitors from 1957 to 1967, Disney finally tore the house down, but discovered it would not go down without a fight. According to Monsanto Magazine, wrecking balls literally bounced off the glass-fiber, reinforced polyester material. Torches, jackhammers, chain saws and shovels did not work. Finally, choker cables were used to squeeze off parts of the house bit by bit to be trucked away.”(2) Monsanto's Disneyfied Vision Of The Future: 1960s: Monsanto, along with chemical partner-in-crime DOW Chemical, produces dioxin-laced Agent Orange for use in the U.S.'s Vietnam invasion. The results? Over 3 million people contaminated, a half-million Vietnamese civilians dead, a half-million Vietnamese babies born with birth defects and thousands of U.S. military veterans suffering or dying from its effects to this day! Monsanto is hauled into court again and internal memos show they knew the deadly effects of dioxin in Agent Orange when they sold it to the government. Outrageously though, Monsanto is allowed to present their own “research” that concluded dioxin was safe and posed no negative health concerns whatsoever. Satisfied, the bought and paid for courts side with Monsanto and throws the case out. Afterwards, it comes to light that Monsanto lied about the findings and their real research concluded that dioxin kills very effectively. A later internal memo released in a 2002 trial admitted “that the evidence proving the persistence of these compounds and their universal presence as residues in the environment is beyond question … the public and legal pressures to eliminate them to prevent global contamination are inevitable. The subject is snowballing. Where do we go from here? The alternatives: go out of business; sell the hell out of them as long as we can and do nothing else; try to stay in business; have alternative products.”(3) Monsanto partners with I.G. Farben, makers of Bayer aspirin and the Third Reich's go-to chemical manufacturer producing deadly Zyklon-B gas during World War II. Together, the companies use their collective expertise to introduce aspartame, another extremely deadly neurotoxin, into the food supply. When questions surface regarding the toxicity of saccharin, Monsanto exploits this opportunity to introduce yet another of its deadly poisons onto an unsuspecting public. 1970s: Monsanto partner, G.D. Searle, produces numerous internal studies which claim aspartame to be safe, while the FDA's own scientific research clearly reveals that aspartame causes tumors and massive holes in the brains of rats, before killing them. The FDA initiates a grand jury investigation into G.D. Searle for “knowingly misrepresenting findings and concealing material facts and making false statements” in regard to aspartame safety. During this time, Searle strategically taps prominent Washington insider Donald Rumsfeld, who served as Secretary of Defense during the Gerald Ford and George W. Bush presidencies, to become CEO. The corporation's primary goal is to have Rumsfeld utilize his political influence and vast experience in the killing business to grease the FDA to play ball with them. A few months later, Samuel Skinner receives “an offer he can't refuse,” withdraws from the investigation and resigns his post at the U.S. Attorney's Office to go work for Searle's law firm. This mob tactic stalls the case just long enough for the statute of limitation to run out and the grand jury investigation is abruptly and conveniently dropped. 1980s: Amid indisputable research that reveals the toxic effects of aspartame and as then FDA commissioner Dr. Jere Goyan was about to sign a petition into law keeping it off the market, Donald Rumsfeld calls Ronald Reagan for a favor the day after he takes office. Reagan fires the uncooperative Goyan and appoints Dr. Arthur Hayes Hull to head the FDA, who then quickly tips the scales in Searle's favor and NutraSweet is approved for human consumption in dried products.This becomes sadly ironic since Reagan, a known jelly bean and candy enthusiast, later suffers from Alzheimers during his second term, one of the many horrific effects of aspartame consumption. Searle's real goal though was to have aspartame approved as a soft drink sweetener since exhaustive studies revealed that at temperatures exceeding 85 degrees Fahrenheit, it “breaks down into known toxins Diketopiperazines (DKP), methyl (wood) alcohol, and formaldehyde.”, becoming many times deadlier than its powdered form! The National Soft Drink Association (NSDA) is initially in an uproar, fearing future lawsuits from consumers permanently injured or killed by drinking the poison. When Searle is able to show that liquid aspartame, though incredibly deadly, is much more addictive than crack cocaine, the NSDA is convinced that skyrocketing profits from the sale of soft drinks laced with aspartame would easily offset any future liability. With that, corporate greed wins and the unsuspecting soft drink consumers pay for it with damaged healths. Coke leads the way once again (remember saccharin?) and begins poisoning Diet Coke drinkers with aspartame in 1983. As expected, sales skyrocket as millions become hopelessly addicted and sickened by the sweet poison served in a can. The rest of the soft drink industry likes what it sees and quickly follows suit, conveniently forgetting all about their initial reservations that aspartame is a deadly chemical. There's money to be made, lots of it and that's all that really matters to them anyway! In 1985, undaunted by the swirl of corruption and multiple accusations of fraudulent research undertaken by Searle, Monsanto purchases the company and forms a new aspartame subsidiary called NutraSweet Company. When multitudes of independent scientists and researchers continue to warn about aspartame's toxic effects, Monsanto goes on the offensive, bribing the National Cancer Institute and providing their own fraudulent papers to get the NCI to claim that formaldehyde does not cause cancer so that aspartame can stay on the market. The known effects of aspartame ingestion are: “mania, rage, violence, blindness, joint-pain, fatigue, weight-gain, chest-pain, coma, insomnia, numbness, depression, tinnitus, weakness, spasms, irritability, nausea, deafness, memory-loss, rashes, dizziness, headaches, seizures, anxiety, palpitations, fainting, cramps, diarrhoea, panic, burning in the mouth. Diseases triggered/mimmicked include diabetes, MS, lupus, epilepsy, Parkinson's, tumours, miscarriage, infertility, fibromyalgia, infant death, Alzheimer's… Source : U.S. Food & Drug Administration. Further, 80% of complaints made to the FDA regarding food additives are about aspartame, which is now in over 5,000 products including diet and non-diet sodas and sports drinks, mints, chewing gum, frozen desserts, cookies, cakes, vitamins, pharmaceuticals, milk drinks, instant teas, coffees, yogurt, baby food and many, many more! Read labels closely and do not buy anything that contains this horrific killer! Amidst all the death and disease, FDA's Arthur Hull resigns under a cloud of corruption and is immediately hired by Searle's public relations firm as a senior scientific consultant. No, that's not a joke! Monsanto, the FDA and many government health regulatory agencies have become one and the same! It seems the only prerequisite for becoming an FDA commissioner is that they spend time at either Monsanto or one of the pharmaceutical cartel's organized crime corps. 1990s: Monsanto spends millions defeating state and federal legislation that disallows the corporation from continuing to dump dioxins, pesticides and other cancer-causing poisons into drinking water systems. Regardless, they are sued countless times for causing disease in their plant workers, the people in surrounding areas and birth defects in babies. With their coffins full from the massive billions of profits, the $100 million dollar settlements are considered the low cost of doing business and thanks to the FDA, Congress and White House, business remains very good. So good that Monsanto is sued for giving radioactive iron to 829 pregnant women for a study to see what would happen to them. In 1994, the FDA once again criminally approves Monsanto's latest monstrosity, the Synthetic Bovine Growth Hormone (rBGH), produced from a genetically modified E. coli bacteria, despite obvious outrage from the scientific community of its dangers. Of course, Monsanto claims that diseased pus milk, full of antibiotics and hormones is not only safe, but actually good for you! Worse yet, dairy companies who refuse to use this toxic cow pus and label their products as“rBGH-free” are sued by Monsanto, claiming it gives them an unfair advantage over competitors that did. In essence, what Monsanto was saying is “yeah, we know rBGH makes people sick, but it's not alright that you advertise it's not in your products.” The following year, the diabolical company begins producing GMO crops that are tolerant to their toxic herbicide Roundup. Roundup-ready canola oil (rapeseed), soybeans, corn and BT cotton begin hitting the market, advertised as being safer, healthier alternatives to their organic non-GMO rivals. Apparently, the propaganda worked as today over 80% of canola on the market is their GMO variety. A few things you definitely want to avoid in your diet are GMO soy, corn, wheat and canola oil, despite the fact that many “natural” health experts claim the latter to be a healthy oil. It's not, but you'll find it polluting many products on grocery store shelves. Because these GM crops have been engineered to ‘self-pollinate,’ they do not need nature or bees to do that for them. There is a very dark side agenda to this and that is to wipe out the world's bee population. Monsanto knows that birds and especially bees, throw a wrench into their monopoly due to their ability to pollinate plants, thus naturally creating foods outside of the company's “full domination control agenda.” When bees attempt to pollinate a GM plant or flower, it gets poisoned and dies. In fact, the bee colony collapse was recognized and has been going on since GM crops were first introduced. To counter the accusations that they deliberately caused this ongoing genocide of bees, Monsanto devilishly buys out Beeologics, the largest bee research firm that was dedicated to studying the colony collapse phenomenon and whose extensive research named the monster as the primary culprit! After that, it's “bees, what bees? Everything's just dandy!” Again, I did not make this up, but wish I had! During the mid-90s, they decide to reinvent their evil company as one focused on controlling the world's food supply through artificial, biotechnology means to preserve the Roundup cash-cow from losing market-share in the face of competing, less-toxic herbicides. You see, Roundup is so toxic that it wipes out non-GMO crops, insects, animals, human health and the environment at the same time. How very efficient! Because Roundup-ready crops are engineered to be toxic pesticides masquerading as food, they have been banned in the EU, but not in America! Is there any connection between that and the fact that Americans, despite the high cost and availability of healthcare, are collectively the sickest people in the world? Of course not! As was Monsanto's plan from the beginning, all non-Monsanto crops would be destroyed, forcing farmers the world over to use only its toxic terminator seeds. And Monsanto made sure farmers who refused to come into the fold were driven out of business or sued when windblown terminator seeds poisoned organic farms. This gave the company a virtual monopoly as terminator seed crops and Roundup worked hand in glove with each other as GMO crops could not survive in a non-chemical environment so farmers were forced to buy both. Their next step was to spend billions globally buying up as many seed companies as possible and transitioning them into terminator seed companies in an effort to wipe out any rivals and eliminate organic foods off the face of the earth. In Monsanto's view, all foods must be under their full control and genetically modified or they are not safe to eat! They pretend to be shocked that their critics in the scientific community question whether crops genetically modified with the genes of diseased pigs, cows, spiders, monkeys, fish, vaccines and viruses are healthy to eat. The answer to that question is obviously a very big “no way!” You'd think the company would be so proud of their GMO foods that they'd serve them to their employees, but they don't. In fact, Monsanto has banned GM foods from being served in their own employee cafeterias. Monsanto lamely responded “we believe in choice.” What they really means is “we don't want to kill the help.” It's quite okay though to force-feed poor nations and Americans these modified monstrosities as a means to end starvation since dead people don't need to eat! I'll bet the thought on most peoples' minds these days is that Monsanto is clearly focused on eugenics and genocide, as opposed to providing foods that will sustain the world. As in Monsanto partner Disney's Sleeping Beauty, the wicked witch gives the people the poisoned GMO apple that puts them to sleep forever! 2000s: By this time Monsanto controls the largest share of the global GMO market. In turn, the US gov't spends hundreds of millions to fund aerial spraying of Roundup, causing massive environmental devastation. Fish and animals by the thousands die within days of spraying as respiratory ailments and cancer deaths in humans spike tremendously. But this is all considered an unusual coincidence so the spraying continues. If you thought Monsanto and the FDA were one and the same, well you can add the gov't to that sorry list now. The monster grows bigger: Monsanto merges with Pharmacia & Upjohn, then separates from its chemical business and rebrands itself as an agricultural company. Yes, that's right, a chemical company whose products have devastated the environment, killed millions of people and wildlife over the years now wants us to believe they produce safe and nutritious foods that won't kill people any longer. That’s an extremely hard-sell, which is why they continue to grow bigger through mergers and secret partnerships. Because rival DuPont is too large a corporation to be allowed to merge with, they instead form a stealth partnership where each agrees to drop existing patent lawsuits against one another and begin sharing GMO technologies for mutual benefit. In layman's terms, together they would be far too powerful and politically connected for anything to stop them from owning a virtual monopoly on agriculture; “control the food supply & you control the people!” Not all is rosy as the monster is repeatedly sued for $100s of millions for causing illness, infant deformities and death by illegally dumping all manner of PCBs into ground water, and continually lying about products safety – you know, business as usual. The monster often perseveres and proves difficult to slay as it begins filing frivolous suits against farmers it claims infringe on their terminator seed patents. In virtually all cases, unwanted seeds are windblown onto farmers' lands by neighboring terminator-seeded farms. Not only do these horrendous seeds destroy the organic farmers' crops, the lawsuits drive them into bankruptcy, while the Supreme Court overturns lower court rulings and sides with Monsanto each time. At the same time, the monster begins filing patents on breeding techniques for pigs, claiming animals bred any way remotely similar to their patent would grant them ownership. So loose was this patent filing that it became obvious they wanted to claim all pigs bred throughout the world would infringe upon their patent. The global terrorism spreads to India as over 100,000 farmers who are bankrupted by GMO crop failure, commit suicide by drinking Roundup so their families will be eligible for death insurance payments. In response, the monster takes advantage of the situation by alerting the media to a new project to assist small Indian farmers by donating the very things that caused crop failures in the country in the first place! Forbes then names Monsanto “company of the year.” Sickening, but true. More troubling is that Whole Foods, the corporation that brands itself as organic, natural and eco-friendly is proven to be anything but. They refuse to support Proposition 37, California's GMO-labeling measure that Monsanto and its GMO-brethren eventually helped to defeat. Why? Because Whole Foods has been in bed with Monsanto for a long time, secretly stuffing its shelves with overpriced, fraudulently advertized “natural & organic” crap loaded with GMOs, pesticides, rBGH, hormones and antibiotics. So, of course they don't want mandatory labelling as that would expose them as the Whole Frauds and Whore Foods that they really are! However, when over twenty biotech-friendly companies including WalMart, Pepsico and ConAgra recently met with FDA in favor of mandatory labelling laws, this after fighting tooth and nail to defeat Prop 37, Whole Foods sees an opportunity to save face and becomes the first grocery chain to announce mandatory labelling of their GMO products…in 2018! Uh, thanks for nothing, Whore. And if you think its peers have suddenly grown a conscience, think again. They are simply reacting to the public's outcry over the defeat of Prop 37 by crafting deceptive GMO-labelling laws to circumvent any real change, thus keeping the status quo intact. To add insult to world injury, Monsanto and their partners in crime Archer Daniels Midland, Sodexo and Tyson Foods write and sponsor The Food Safety Modernization Act of 2009: HR 875. This criminal “act” gives the corporate factory farms a virtual monopoly to police and control all foods grown anywhere, including one's own backyard, and provides harsh penalties and jail sentences for those who do not use chemicals and fertilizers. President Obama decided this sounded reasonable and gave his approval. With this Act, Monsanto claims that only GM foods are safe and organic or homegrown foods potentially spread disease, therefore must be regulated out of existence for the safety of the world. If eating GM pesticide balls is their idea of safe food, I would like to think the rest of the world is smart enough to pass. As further revelations have broken open regarding this evil giant's true intentions, Monsanto crafted the ridiculous HR 933 Continuing Resolution, aka Monsanto Protection Act, which Obama robo-signed into law as well.This law states that no matter how harmful Monsanto's GMO crops are and no matter how much devastation they wreak upon the country, U.S. federal courts cannot stop them from continuing to plant them anywhere they choose. Yes, Obama signed a provision that makes Monsanto above any laws and makes them more powerful than the government itself. We have to wonder who's really in charge of the country because it's certainly not him! There comes a tipping point though when a corporation becomes too evil and the world pushes back…hard! Many countries continue to convict Monsanto of crimes against humanity and have banned them altogether, telling them to “get out and stay out!” The world has begun to awaken to the fact that the corporate monster does not want control over the global production of food simply for profit's sake. No, it's become clear by over a century of death & destruction that the primary goal is to destroy human health and the environment, turning the world into a Mon-Satanic Hell on Earth! Research into the name itself reveals it to be latin, meaning “my saint,” which may explain why critics often refer to it as “Mon-Satan.” Even more conspiratorially interesting is that free masons and other esoteric societies assigned numbers to each letter in our latin-based alphabet system in a six system. Under that number system, what might Monsanto add up to? Why, of course 6-6-6! Know that all is not lost. Evil always loses in the end once it is widely exposed to the light of truth as is occurring now. The fact that the Monsanto-led government finds it necessary to enact desperate legislation to protect its true leader proves this point. Being evicted elsewhere, the United States is Monsanto's last stand so to speak. Yet, even here many have begun striking back by protesting against and rejecting GMO monstrosities, choosing to grow their own foods and shop at local farmers markets instead of the Monsanto-supported corporate grocery chains. The awakening people are also beginning to see they have been misled by corporate tricksters and federal government criminals poisoned by too much power, control and greed, which has resulted in the creation of the monstrous, out-of-control corporate beast. Notes: (1,3) Best Meal | (2) Source Watch Related: Monsanto Insiders Dump Stock as the Truth about GMOs Spreads across Wall Street Monsanto Protection Act May Soon Be Repealed Thanks to Activism Facebook And Monsanto Are Basically Owned By The Same People 5 Million Farmers Sue Monsanto for $7.7 Billion... Read More: https://www.whydontyoutrythis.com/2015/09/must-read-the-complete-history-of-monsanto-the-worlds-most-evil-corporation.html?fbclid=IwAR1qGrkio5XjYTdishGNPpvxDMdlhBqgCfbImj73DCMl9QY8oycZpcs_0_4&m=1

INEDIBLE THOUGHTS.
Inspired by the movie 'Parasites.'

The intricacies of climate change are
inedible thoughts for many and keeps
this poet in poverty and cultural starvation...
When speaking the truth becomes
comedy for deniers and is laughed at by
their obsequious followers, each fact behind
the truth is then easily ignored by those in power and also
their laughing sycophants who refuse to face the truth...
To be an obsequious sycophant is not to be a
person but an object of derision
and I refuse to bend my knees to corrupt authorities
or to corporate dominators who act like royalty while refusing to
accept this important fact.
Without Nature all life on Earth
will cease to exist and those few human individuals
who profit by exploiting Nature and who enjoy the servile quiescence of others detest this powerful and
dominating science-based fact because it will force them
to lose control over their obsequious sycophants.

ALTERNATIVE NEWS
A Scientist Explains Why He Believes Aluminum Is “Almost Certainly” Playing A Role in Autism. Published 6 days ago on February 19, 2020, By Arjun Wallace Staff Writer,

SHARE TWEET
IN BRIEF
The Facts: Dr. Christopher Exley, a Professor in Bioinorganic Chemistry at Keele University explains why he believes aluminum is playing some sort of role in Autism. And no, he doesn't mean that aluminum is directly causing autism.
Reflect On: How safe are our common medications? How much safety testing have they gone through? How much is still unknown?

A study published in 2018 discovered high amounts of aluminum in the brain tissue of people with autism. There is a picture from the study showing aluminum in brain tissue. Five people were used in the study, comprising of four males and one female, all between the ages of 14-50. Each of their brains contained what the authors considered unsafe and high amounts of aluminum compared to brain tissues of patients with other diseases where high brain aluminum content is common, like Alzheimer’s disease, for example.

The authors state that,

Human exposure to aluminum has been implicated in ASD with conclusions being equivocal [7], [8], [9], [10]. To-date the majority of studies have used hair as their indicator of human exposure to aluminum while aluminum in blood and urine have also been used to a much more limited extent. Pediatric vaccines that include an aluminum adjuvant are an indirect measure of infant exposure to aluminum and their burgeoning use has been directly correlated with the increasing prevalence of ASD [11]. Animal models of ASD continue to support a connection with aluminum and to aluminum adjuvants used in human vaccinations in particular [12].

They note that the aluminum content of brain tissues from donors with a diagnosis of ASD was “extremely high” (Table 1). And they make the point that they “recorded some of the highest values for brain aluminum content ever measured in healthy or diseased tissues in these male ASD donors.”

My group has measured the aluminum content of probably more than one-hundred human brains, and these brain tissues taken from the individuals with a diagnosis of autism were some of the highest we’ve measured, bar none….In this relatively young group of people, some 13, 14, 15 years of age, we saw more aluminum than we’ve seen in almost any other circumstance, so this in itself is a very important finding.

Perhaps equally important if not more important were the microscopy studies. The microscopy studies enabled us to identify where the aluminum was in the brain tissue. When we looked at our brains of the people with a diagnosis of autism, we found something completely different, something we’ve never seen before. We found that the majority of aluminum was actually inside cells, intracellular.

Some of it was inside neurons, but actually, the majority of it was inside non-neuronal cell populations. So we found that these cells were heavily loaded with aluminum. We also saw evidence that cells in the lymph, and in the blood, were passing into the brain. So they were carrying with them a cargo of aluminum, from the body into the brain. This is the first time in any human brain tissue that we have seen this so this is a standout and as yet unique observation in autism. For myself, it very much implicates aluminum in the etiology of autism, that doesn’t mean that aluminum causes it, but it means it’s almost certainly playing a role. – Dr. Christopher Exley, a Professor in Bioinorganic Chemistry at Keele University, lead author of the study cited above. In this interview, Exley answers a lot of questions, but the part that caught my attention, similar to what was said above, was:

We have looked at what happens to the aluminum adjuvant when it’s injected and we have shown that certain types of cells come to the injection site and take up the aluminum inside them. You know, these same cells we also see in the brain tissue in autism. So, for the first time we have a link that honestly I had never expected to find between aluminum as an adjuvant in vaccines and that same aluminum potentially could be carried by those same cells across the blood-brain barrier into the brain tissue where it could deposit the aluminum and produce a disease, Encephalopathy (brain damage), it could produce the more severe and disabling form of autism. This is a really shocking finding for us.

How Does Aluminum In Vaccines Differ From Other Sources of Aluminum?
Despite the fact that only a small amount of aluminum is contained in aluminum-containing vaccines, it’s delivery to the body is different than the aluminum we take in from our food, for example.

When you inject aluminum, it goes into a different compartment of your body. It doesn’t come into that same mechanism of excretion. So, and of course, it can’t because that’s the whole idea of aluminum adjuvants, aluminum adjuvants are meant to stick around and allow that antigen to be presented over and over and over again persistently, otherwise you wouldn’t put an adjuvant in the vaccine in the first place. It can’t be inert, because if it were inert it couldn’t do the things it does. It can’t be excreted because again it couldn’t provide that prolonged exposure of the antigen to your immune system. – Dr. Christopher Shaw – Canadian neuroscientist and professor of ophthalmology at the University of British Columbia (source)

STAY AWARE
SUBSCRIBE TO OUR NEWSLETTER

Email address
SUBSCRIBE
Many scientists presented facts about vaccines and vaccine safety at the recent Global Health Vaccine Safety summit hosted by the World Health Organization in Geneva, Switzerland, and the topic of adjuvants was brought up.

Dr. Martin Howell Friede, Coordinator of Initiative For Vaccine Research at the World Health Organization, brought up the topic of vaccine adjuvants like aluminum, for example. In certain vaccines, without these adjuvants the vaccine simply doesn’t work. Dr. Friede mentioned that there are clinical studies that blame adjuvants for adverse events seen as a result of administering vaccines, and how people in general often blame adverse reactions to vaccines being the result of the vaccine adjuvant. He mentioned aluminum specifically.

He showed concern given the fact that “without adjuvants, we are not going to have the next generation of vaccines.”

He also stated that:

When we add an adjuvant, it’s because it is essential. We do not add adjuvants to vaccines because we want to do so, but when we add them it adds to the complexity. And I give courses every year on ‘how do you develop vaccines’ and ‘how do you make vaccines’ and the first lesson is, while you are making your vaccine if you can avoid using an adjuvant, please do so. Lesson two is, if you’re going to use an adjuvant, use one that has a history of safety, and lesson three is, if you’re not going to do that, think very carefully.

So, does the aluminum adjuvant in vaccines have a “history of safety?”

According to a study published as far back as 2011 in Current Medical Chemistry

Aluminum is an experimentally demonstrated neurotoxin and the most commonly used vaccine adjuvant. Despite almost 90 years of widespread use of aluminum adjuvants, medical science’s understanding about their mechanisms of action is still remarkably poor. There is also a concerning scarcity of data on toxicology and pharmacokinetics of these compounds. In spite of this, the notion that aluminum in vaccines is safe appears to be widely accepted. Experimental research, however, clearly shows that aluminum adjuvants have a potential to induce serious immunological disorders in humans. (source)

A year after this,

A study published in BioMed Central (also cited in the study above) in 2013 found more cause for concern:

Intramuscular injection of alum-containing vaccine was associated with the appearance of aluminum deposits in distant organs, such as spleen and brain where they were still detected one year after injection. Both fluorescent materials injected into muscle translocated to draining lymph nodes (DLNs) and thereafter were detected associated with phagocytes in blood and spleen. Particles linearly accumulated in the brain up to the six-month endpoint; they were first found in perivascular CD11b+ cells and then in microglia and other neural cells. DLN ablation dramatically reduced the biodistribution. Cerebral translocation was not observed after direct intravenous injection but significantly increased in mice with chronically altered blood-brain-barrier. Loss/gain-of-function experiments consistently implicated CCL2 in systemic diffusion of Al-Rho particles captured by monocyte-lineage cells and in their subsequent neuro-delivery. Stereotactic particle injection pointed out brain retention as a factor of progressive particle accumulation…

The study went on to conclude that “continuously escalating doses of this poorly biodegradable adjuvant in the population may become insidiously unsafe.”

These authors followed up in and published a study study in 2015 emphasized:

Evidence that aluminum-coated particles phagocytosed in the injected muscle and its draining lymph nodes can disseminate within phagocytes throughout the body and slowly accumulate in the brain further suggests that alum safety should be evaluated in the long term.

I think it’s also important to mention that in 2018, a paper published in the Journal of Inorganic Biochemistry found that almost 100 percent of the intramuscularly injected aluminum in mice as vaccine adjuvants was absorbed into the systemic circulation and traveled to different sites in the body such as the brain, the joints, and the spleen, where it accumulated and was retained for years post-vaccination. (source)

The Takeaway
This is simply information, it’s science, which never ceases to question. It should not be labeled as “anti-vax,” and those who believe that aluminum adjuvants should not be considered a cause for concern should simply explain why, and provide evidence and studies to back up their points. I have a hard time seeing why most people would not want to question this, as there is clearly more room to make our vaccines safer and more effective.

BREAKING NEWS: Our house is on fire!

Ashley: Student Activist standing with Greenpeace Canada.
to me

Nelson,
Our house is on fire. We need to wake up.

Just before dawn, alongside Greenpeace activists, I’ve welcomed federal cabinet ministers back to the House of Commons with a fiery demand to reject the Teck Frontier Mine.

If built, the massive Teck Frontier tar sands mine would be one of the largest — and possibly the largest — tar sands mine ever built. And the Trudeau government has to decide whether to approve or reject it anytime now. Don’t you think it’s time for us to move away from fossil fuels? Reject Teck Frontier now.

From Russia to Australia, 2019 was marked by gigantic and unforgiving fires. Reducing life to ashes, destroying homes and habitats, scarring minds with images that cannot be forgotten, the flames of the climate crisis are now very real and they are getting closer.

Now is the time for shock and awe, to be righteous as we demand respect for climate promises our government has made. No one is fooled: existing laws are not strong enough and industries and corporations can’t just snatch what they want from nature. No one is fooled when politicians say pipelines are built to finance a clean energy transition. No one is fooled when in the "era of reconciliation", violence is used against indigenous people to serve greedy interests. No one is fooled by the promise that we can reach carbon neutrality by 2050 and still build a project as destructive as the Teck tar sands mega-mine.

I will not stand by and do nothing. I can no longer accept this.

Our democratic duty isn’t something we exercise just every four years, but we must exercise it on a daily basis. And when our government goes off the rails, we need to put it back on track. There are only 10 days left to convince Justin Trudeau's cabinet to do the right thing and reject Teck Frontier.

Email Justin Trudeau’s cabinet and challenge your friends and family to do the same. Trudeau is under enormous pressure from oil lobbyists to approve this project and there is not much time left to get him to make the right decision.

When I think of all the struggles, mobilizations, and energy that we are putting into solving the climate emergency, I tell myself that the worst that can happen if we win is that we will gain a fairer society, thriving ecosystems that are abundant with life, clean cities and healthy populations. To gain all of this, I will put myself out there with great pleasure and take the risk to stand up for what I believe in.

And this is why I am here today.

Thank you for all that you do.

Ashley
Student activist

Attention World Leaders.

ATTENTION WORLD LEADERS
STOP THE POLLUTION!

Give up Oil and Gas and Plastics because the alternative is climate change leading to world-wide droughts, crop failures, forest fires, inland floods, and killer pandemics.
The: Arctic, Antarctic. and Greenland ice glaciers are melting and that melt has the effect of raising the level of our Oceans. The Co2 level created from pollution in the atmosphere creates a Green-house effect and that, in turn, melts the Glaciers and warms the Oceans which in turn creates Typhoons and Hurricanes. The science proving this is clear and precise and irrefutable and political and corporate leaders who decide to ignore the facts are acting dangerously irresponsible! They are reaching the point of criminal negligence.
IT IS FAR PAST THE TIME TO STOP THE POLLUTION!

GM Watch

News and comment on genetically modified foods and their associated pesticides

"Healthy" soybean oil causes genetic changes in the brain linked to neurological disease.
Details
Published: 04 February 2020
Share
Soya oil bottle

Study shows the most widely consumed edible oil in the US could be bad for the brain – and that oil from soybeans genetically engineered to be healthier is just as bad

Eating soybean oil has already been linked to obesity and diabetes.[1] Now new research from scientists at the University of California Riverside shows it could also adversely affect neurological conditions like autism, Alzheimer’s disease, Parkinson's disease, anxiety, schizophrenia, and depression.[2]

The study also debunks advertising claims that the low-linoleic acid Plenish soybean, developed by DuPont Pioneer, has a "healthier nutritional profile" when "health" is viewed holistically.

Soybean oil is used for fast food frying, added to packaged foods, and fed to livestock. It is by far the most widely produced and consumed edible oil in the US, according to the US Department of Agriculture. The Plenish soybean is genetically engineered to have low linoleic acid, resulting in an oil that's claimed to be healthy because it generates less trans fats during cooking. Trans fats are linked with heart disease.

The new study, published in the journal Endocrinology, compared mice fed three different diets high in fat: "conventional" soybean oil (high in linoleic acid), Plenish soybean oil, and coconut oil. There was also an additional low-fat control diet.

The researchers don't define "conventional" soybean oil in their paper but it's almost certain that it's derived from GM Roundup Ready soybeans, as around 94% of the US soybean crop is of this type and the researchers don't describe in their paper what would be a complex process of sourcing oil from non-GMO beans. The corresponding author, Margarita Curras-Collazo, a UCR associate professor of neuroscience, did not respond to GMWatch's requests for clarification on this.

The researchers performed a transcriptomic analysis, a type of molecular analysis that looks at gene expression, on all groups of animals.

They did not find any difference between the GM low-linoleic and "conventional" soybean oil’s effects on the brain. Specifically, the scientists found pronounced effects of the oil on the hypothalamus, where a number of critical processes take place.

The results showed that compared to the coconut oil and low-fat control diets, the two soybean oil-based diets resulted in a significant dysregulation of more than 100 hypothalamic genes, including those involved in neurochemical and neuroendocrine pathways and metabolic and neurological disorders.

“The hypothalamus regulates body weight via your metabolism, maintains body temperature, is critical for reproduction and physical growth as well as your response to stress,” said Margarita Curras-Collazo.

The team determined a number of genes in mice fed soybean oil were not functioning correctly. One such gene produces the “love” hormone, oxytocin. In soybean oil-fed mice, levels of oxytocin in the hypothalamus went down.

The research team believe that their discovery could have ramifications not just for energy metabolism, but also for proper brain function and diseases such as autism or Parkinson’s disease. However, it is important to note there is no proof the oil causes these diseases.

A separate study from UCR researchers found in 2015 that soybean oil induces obesity, diabetes, insulin resistance, and fatty liver in mice.[3] Then in a 2017 study, the same group learned that if soybean oil is genetically engineered to be low in linoleic acid, it induces less obesity and insulin resistance.[4]

With regard to the new study on brain effects, the research team has not yet isolated which chemicals in the oil are responsible for the changes they found in the hypothalamus. But they have ruled out two candidates. It is not linoleic acid, since the modified oil also produced genetic disruptions; nor is it stigmasterol, a cholesterol-like chemical found naturally in soybean oil.

Identifying the compounds responsible for the negative effects is an important area for the team’s future research.

“This could help design healthier dietary oils in the future,” said Poonamjot Deol, an assistant project scientist in Sladek’s laboratory and first author on the study.

“The dogma is that saturated fat is bad and unsaturated fat is good. Soybean oil is a polyunsaturated fat, but the idea that it’s good for you is just not proven,” Sladek said.

Indeed, coconut oil, which contains saturated fats, produced very few changes in the hypothalamic genes. GMWatch readers will note that there's no need to "design" healthier oils when naturally healthy oils already exist – coconut oil being a case in point.

“If there’s one message I want people to take away, it’s this: reduce consumption of soybean oil,” Deol said.

Additionally, the team notes the findings only apply to soybean oil — not to other soy products or to other vegetable oils.

“Do not throw out your tofu, soymilk, edamame, or soy sauce,” said Frances Sladek, a UCR toxicologist and professor of cell biology. “Many soy products only contain small amounts of the oil, and large amounts of healthful compounds such as essential fatty acids and proteins.”

GMWatch would add that if you eat soy products, it's vital to source organic and non-GMO soy, at the very least to avoid residues of the glyphosate that can be present at high levels in GM glyphosate-tolerant soy. GM soy has been found in animal feeding studies to produce adverse effects on the liver, pancreas and male testes. No one knows if this is due to the glyphosate residues, or some mutagenic effect of the GM process on the soy plants, or both.

Looking at the bigger picture, the new study has a lesson for those who enthuse about nutritionally enhanced GM foods. That is that a healthy nutritional profile should be defined holistically, not just by looking at one or a few nutrients. It is counter-productive to engineer a food that is meant to be heart-healthy if it is likely to damage brain function.

Notes

1. See:
* Costa CA, Carlos AS, dos Santos Ade S, Monteiro AM, Moura EG, Nascimento-Saba CC. Abdominal adiposity, insulin and bone quality in young male rats fed a high-fat diet containing soybean or canola oil. Clinics 2011;66(10):1811–1816.
* Deol P, Fahrmann J, Yang J, Evans JR, Rizo A, Grapov D, Salemi M, Wanichthanarak K, Fiehn O, Phinney B, Hammock BD, Sladek FM. Omega-6 and omega-3 oxylipins are implicated in soybean oil-induced obesity in mice. Sci. Rep. 2017;7(1):12488.
* Deol P, Evans JR, Dhahbi J, Chellappa K, Han DS, Spindler S, Sladek FM. Soybean oil is more obesogenic and diabetogenic than coconut oil and fructose in mouse: potential role for the liver. PLoS One 2015;10(7):e0132672. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0132672
* Mamounis KJ, Yasrebi A, Roepke TA. Linoleic acid causes greater weight gain than saturated fat without hypothalamic inflammation in the male mouse. J. Nutr. Biochem. 2017;40:122–131.

2. Deol P et al. Dysregulation of hypothalamic gene expression and the oxytocinergic system by soybean oil diets in male mice. Endocrinology 2020:bqz044. https://doi.org/10.1210/endocr/bqz044

3. Deol P et al. Deol P, Evans JR, Dhahbi J, Chellappa K, Han DS, Spindler S, Sladek FM. Soybean oil is more obesogenic and diabetogenic than coconut oil and fructose in mouse: potential role for the liver. PLoS One 2015;10(7):e0132672. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0132672

4. Deol P, Fahrmann J, Yang J, Evans JR, Rizo A, Grapov D, Salemi M, Wanichthanarak K, Fiehn O, Phinney B, Hammock BD, Sladek FM. Omega-6 and omega-3 oxylipins are implicated in soybean oil-induced obesity in mice. Sci. Rep. 2017;7(1):12488.
---
The new study:
Dysregulation of hypothalamic gene expression and the oxytocinergic system by soybean oil diets in male mice
Poonamjot Deol et al (2020)
Endocrinology, bqz044
Published: 08 January 2020
https://doi.org/10.1210/endocr/bqz044 (open access)

Abstract

Soybean oil consumption has increased greatly in the past half-century and is linked to obesity and diabetes. To test the hypothesis that soybean oil diet alters hypothalamic gene expression in conjunction with metabolic phenotype, we performed RNA-seq analysis using male mice fed isocaloric, high-fat diets based on conventional soybean oil (high in linoleic acid, LA), a genetically modified, low-LA soybean oil (Plenish) and coconut oil (high in saturated fat, containing no LA). The two soybean oil diets had similar, albeit non-identical, effects on the hypothalamic transcriptome, whereas the coconut oil diet had a negligible effect compared to a low-fat control diet. Dysregulated genes were associated with inflammation, neuroendocrine, neurochemical, and insulin signaling. Oxt was the only gene with metabolic, inflammation and neurological relevance upregulated by both soybean oil diets compared to both control diets. Oxytocin immunoreactivity in the supraoptic and paraventricular nuclei of the hypothalamus was reduced while plasma oxytocin and hypothalamic Oxt were increased. These central and peripheral effects of soybean oil diets were correlated with glucose intolerance but not body weight. Alterations in hypothalamic Oxt and plasma oxytocin were not observed in coconut oil diet enriched in stigmasterol, a phytosterol found in soybean oil. We postulate that neither stigmasterol nor LA is responsible for effects of soybean oil diets on oxytocin and that Oxt mRNA levels could be associated with the diabetic state. Given its ubiquitous presence in the American diet, the observed effects of soybean oil on hypothalamic gene expression could have important public health ramifications.

TRUMP DEBTS

DOES DONALD TRUMP PAY HIS DEBTS?

FROM A NEW YORK TIMES MAGAZINE
FEATURE.

"The Money Behind Trump’s Money
The inside story of the president and Deutsche Bank, his lender of last resort.

By David Enrich
Feb. 4, 2020, 5:00 a.m. ET

24
One Day in early 2017, Mike Offit went to the Yale Club in Manhattan for a lunch hosted by a group called Business Executives for National Security. Offit, who has a craggy face and shoulder-­length hair, had spent much of his career in banking, but that had ended nearly two decades earlier. Since then, he had puttered around the outskirts of finance, dabbled in journalism and even published a novel about a pair of murders at a fictional German-­owned Wall Street bank that bore a striking resemblance to the one that he worked for until 1998: ­Deutsche Bank.

These days, Offit had time on his hands, which is how he found himself at the Yale Club that afternoon. Slanting winter sunlight illuminated the white-­columned walls of the club’s dining room. Offit was chatting with an American military officer about weaponry when his iPhone buzzed. He saw an email from the White House Executive Office of the President. How strange, Offit thought.

The message contained a PDF file: a scanned printout of an email he had sent Donald Trump several months earlier, in the waning days of the presidential campaign. Offit had known Trump for decades. At ­Deutsche Bank, he had lined up huge loans to finance Trump’s construction and renovation of landmark Manhattan skyscrapers, at a time when the default-­prone real estate developer and casino magnate was no longer able to get loans from most mainstream financial institutions. The two men stayed in touch afterward. Offit’s 2014 book, “Nothing Personal,” even featured a blurb from Trump: “Michael Offit offers a colorful insight into how the big money is made — and/or taken — on Wall Street.”

[This article is adapted from David Enrich’s forthcoming book, “Dark Towers: Deutsche Bank, Donald Trump, and an Epic Trail of Destruction.”]

In October 2016, Offit tried to return the favor. Democrats were pillorying Trump’s shaky — not to mention murky — personal finances, including his companies’ chronic bankruptcies. Offit thought he might dispense a little advice to his erstwhile client. On a Friday evening, he emailed Trump a lengthy message, explaining that the defense Trump was offering at the time — that he was simply using the bankruptcy law in an advantageous way — wasn’t resonating with voters. “I believe there is a much better answer, that may help defuse this issue, and am just arrogant enough to suggest it,” Offit wrote.

He advised Trump to claim that his companies had been forced to declare bankruptcy, the victims of greedy hedge funds so obsessed with wringing every last dollar out of him that they refused to let him renegotiate his crushing debts. Was this true? Not really. But it sounded good, and the line of attack meshed with Trump’s populist rhetoric on the campaign trail.

Unlock more free articles.
Create an account or log in
Offit got no response. He wasn’t even sure that Trump had read the email. But here, months later, was Trump’s unmistakable black Sharpie scrawl across the top of the message he had sent: “Mike — Such a cool letter. Best wishes, Donald.”

“Look at this!” Offit exclaimed to the officer. “I just got a note from the president!”

“What do you mean, you got a note from the president?”

Offit handed him the iPhone so he could see for himself. The man’s eyes widened. “Wow,” he said. “That’s more of a response than we can get out of him.”

ImageTrump International Hotel, Washington: $170 million loan (2014).
Trump International Hotel, Washington: $170 million loan (2014).Credit...Brooks Kraft/Getty Images
The officer asked what Offit’s connection was to the president. Offit replied, “I loaned him half a billion dollars.”

The roughly $425 million that Offit helped arrange for Trump back in 1998 was the start of a very long, very complicated relationship between ­Deutsche Bank and the future president. Over the course of two decades, the bank lent him more than $2 billion — so much that by the time he was elected, ­Deutsche Bank was by far his biggest creditor. Against all odds, Trump paid back most of what he owed the bank. But the relationship cemented ­Deutsche Bank’s reputation as a reckless institution willing to do business with clients nobody else would touch. And it has made the company a magnet for prosecutors, regulators, and lawmakers hoping to penetrate the president’s opaque financial affairs.

Last April, congressional Democrats subpoenaed ­Deutsche Bank for its records on Trump, his family members and his businesses. The Trump family sued to block the bank from complying; after two federal courts ruled against the Trumps, the Supreme Court has agreed to hear the case, with oral arguments expected in the spring. State prosecutors, meanwhile, are investigating the bank’s ties with Trump, too. The F.B.I. has been conducting its own wide-­ranging investigation of ­Deutsche Bank, and people connected to the bank told me they have been interviewed by special agents about aspects of the Trump relationship.

If they ever become public, the bank’s Trump records could serve as a Rosetta Stone to decode the president’s finances. Executives told me that the bank has, or at one point had, portions of Trump’s personal federal income tax returns going back to around 2011. (­Deutsche Bank lawyers told a federal court last year that the bank does not have those returns; it is unclear what happened to them. The Trump Organization did not respond to multiple requests for comment.) The bank has documents detailing the finances and operations of his businesses. And it has records about internal deliberations over whether and how to do business with Trump — a paper trail that most likely reflects some bank employees’ concerns about potentially suspicious transactions that they detected in the family’s accounts.

One reason all these files could be so illuminating is that the bank’s relationship with Trump extended well beyond making simple loans. ­Deutsche Bank managed tens of millions of dollars of Trump’s personal assets. The bank also furnished him with other services that have not previously been reported: providing sophisticated financial instruments that shielded him from risks and outside scrutiny, and making introductions to wealthy Russians who were interested in investing in Western real estate. If Trump cheated on his taxes, ­Deutsche Bank would probably know. If his net worth is measured in millions, not billions, ­Deutsche Bank would probably know. If he secretly got money from the Kremlin, ­Deutsche Bank would probably know.>

Until the 1990s, ­Deutsche Bank was a provincial German company with a limited presence outside Europe. Today it is a $1.5 trillion colossus, one of the world’s largest banks, with offices in 59 countries — and, thanks to its well-­documented pattern of violating laws, an international symbol of greed, recklessness and hubris. Its rap sheet includes manipulating international currency markets; playing a central role in rigging a crucial benchmark interest rate known as Libor; whisking billions of dollars in and out of Iran, Syria, Myanmar and other countries in violation of sanctions; laundering billions of dollars on behalf of Russian oligarchs, among many others; and misleading customers, investors and American, German and British regulators.

­Deutsche Bank’s envelope-­pushing helped it become the global power player it is today, but it also left the company dangerously frail. Its books remain stuffed with trillions of dollars of risky derivatives — the sort of instruments that many other banks have disposed of since the 2008 financial crisis but that persist as a kind of unexploded ordnance in ­Deutsche Bank’s accounts, threatening to inflict severe damage on the bank and the broader financial system if something were to cause them to detonate. Its financial cushions to absorb future shocks are threadbare. Its core businesses are not performing well; the bank lost $5.8 billion last year. Because of Deutsche Bank’s size and its connections with hundreds of other major banks around the world, serious problems could spread, virus­like, to other financial institutions. The International Monetary Fund a few years ago branded ­Deutsche Bank “the most important net contributor to systemic risks” in the global banking system.

­Deutsche Bank’s relationship with Trump, rather than being an odd outlier, is a kind of object lesson in how the bank lost its way. The company was hungry for growth, especially in the United States, and it was happy to cozy up to clients that better-­established players viewed as too damaged or dangerous. Along the way, it missed one opportunity after another to extricate itself from the Trump relationship or at least slow its expansion. With hindsight, the procession of miscues and bad decisions appears almost comical.

I have spent the past two years interviewing dozens of ­Deutsche Bank executives about the Trump relationship, among other subjects. Quite a few look back at the relationship with a mixture of anger and regret. They blame a small group of bad bankers for blundering into a trap that would further damage ­Deutsche Bank’s name and guarantee years of political and prosecutorial scrutiny. But that isn’t quite right; in fact, the Trump relationship was repeatedly blessed by executives up and down the bank’s organizational ladder. The cumulative effect of those decisions is that a German company — one that most Americans have probably never heard of — played a large role in positioning a strapped businessman to become president of the United States.

Image
40 Wall Street, New York: $125 million loan (1998).
40 Wall Street, New York: $125 million loan (1998).Credit...Raymond Boyd/Getty Images
Founded in 1870, ­Deutsche Bank spent most of its first 12 decades helping mighty German companies like Siemens expand internationally, as well as bankrolling infrastructure projects — primarily railroads — in Europe, Asia and North America. (Before and during World War II, the bank was a leading financier of the Nazis, helping to pay for projects including the construction of Auschwitz.) As the Iron Curtain fell, ­Deutsche Bank executives saw an opportunity to surf the tide of globalization and become a truly global institution.

The modern multinational corporation — operating in dozens of countries; buying and selling products and raw materials in a slew of different currencies; seeking to protect itself from volatile prices, fluctuating foreign-­exchange rates and sundry unforeseeable risks — needed banks that would provide much more than run-of-the-mill loans. Now financial institutions were expected to underwrite stock and bond offerings, enable seamless transactions across international borders and in multiple currencies and create financial instruments known as derivatives that customers could use to insulate themselves from big swings in interest rates, dairy prices, the weather and the like. Top Wall Street banks were beginning to offer these services to German companies and even the German government. To defend its turf, ­Deutsche Bank needed to learn to compete with the Americans.

In 1989, the bank took its first small step into this new financial world by acquiring a venerable British investment bank, Morgan Grenfell. Then, in 1995, ­Deutsche Bank hired a small crew of traders from Merrill Lynch — at the time one of Wall Street’s leading firms — led by a charismatic and impulsive salesman named Edson Mitchell. The American and British governments were rolling back regulations on the banking industry, and the giants of Wall Street were getting bigger, fast. ­Deutsche Bank needed to act quickly to have any chance of catching up. Over the next couple of years, Mitchell’s team spent billions of dollars hiring thousands of bankers and traders from just about every major investment bank — perhaps the greatest mass migration in Wall Street’s history. One recruit was Mike Offit; another was Justin Kennedy, a son of the Supreme Court justice Anthony Kennedy.

Offit and Kennedy were traders at Goldman Sachs together, creating and selling mortgage bonds and working for Steven Mnuchin, now the Treasury secretary. By the time ­Deutsche Bank came knocking in the late 1990s, both men were ready for a change. (Plus, Offit claims, Mnuchin stiffed him when it came to compensation.) The German bank lured them, as it had others, by promising them the freedom, budget and entrepreneurial culture to help establish the bank as a formidable player on Wall Street — a euphemistic way of saying that the bank had a higher tolerance for risk than many rivals. Come to ­Deutsche Bank, and you could do bigger trades. Offer larger loans. Make bolder acquisitions. Earn more money.

Offit and Kennedy were hired to build, essentially from scratch, a machine to package giant loans — for skyscrapers, hotels and other commercial real estate projects — into salable securities. At the time, selling and trading these mortgage-­backed bonds was one of the hottest businesses on Wall Street. Success would not only be remunerative; it would help burnish ­Deutsche Bank’s credentials as a serious challenger to the Wall Street elite.

Among the first steps was finding recipients for the loans — and that is how Donald Trump became a customer of ­Deutsche Bank. Two decades after striking out on his own in real estate, Trump was then at a low point of his career. He had recently defaulted on his debts to a number of large Wall Street banks — the consequence of many hundreds of millions of dollars of unwise, overleveraged investments in the casino and hotel industries — and was eager to find a financier willing to look past these sins. In 1998, Offit arranged to lend hundreds of millions of dollars to finance Trump’s gut renovations of an Art Deco tower at 40 Wall Street and his construction of a skyscraper next to
Trump, however, had a nasty tendency to stiff his business partners and associates. There was an extensive list of Trump contractors, vendors and lawyers who had to settle for a fraction of what they were owed after Trump threatened to pay nothing at all. Banks, from Wall Street powerhouses like JPMorgan to foreign lenders like Britain’s NatWest, had fared little better. Time after time, Trump’s casino companies defaulted on their debts, filed for bankruptcy and ultimately agreed to pay back their creditors pennies on the dollar.

Image
Trump World Tower, New York: $300 million loan guarantee (1998).
Trump World Tower, New York: $300 million loan guarantee (1998).Credit...Carlo Allegri/Reuters
Merrill Lynch learned this lesson the hard way when it helped Trump sell $675 million of bonds to pay for work on his Taj Mahal casino on the Atlantic City boardwalk in 1988. The gaudy casino — the world’s largest — opened its doors two years later, bedecked with bright-­colored onion domes and laden with debt. Within months, it defaulted on the bonds. The unpleasant task of mopping up this mess fell to a Merrill executive named Seth Waugh. Trump threatened to tie his lenders up in years of bankruptcy-­court litigation if they didn’t agree to let him largely off the hook for what he owed. Nobody doubted Trump’s litigiousness, and Waugh and his Merrill colleagues ultimately accepted what amounted to deep losses on the bonds.

In 2000, Waugh joined ­Deutsche Bank. Perma-­tanned and with long, floppy hair, Waugh developed a reputation among some ­Deutsche Bank colleagues for being a bit of a lightweight. They derided him for spending more time on the golf course than he did in the office. (Today Waugh is the chief executive of the Professional Golfers’ Association of America.) But he enjoyed the confidence of one of ­Deutsche Bank’s highest-­ranking executives, Josef Ackermann, who helped recruit him from Merrill Lynch. In 2001, Waugh learned that ­Deutsche Bank was planning to lend Trump about $500 million to use as he wished — basically an unrestricted cash infusion to stabilize his flagging finances. Having witnessed up close the carnage that Trump could inflict on imprudent financial institutions, Waugh was in no hurry to repeat the experience.

The loan that was being offered now wouldn’t have required Trump to put up any hard assets as collateral; he was requesting to borrow $500 million against the $1 billion of “good will” that Trump claimed was associated with his name. That made the transaction even riskier: If Trump stopped repaying, ­Deutsche Bank would have no easy way to get its money back. Waugh voiced strong objections to the loan, and the deal died.

Waugh would soon be named the head of Deutsche Bank’s American businesses, and he had the power to put a stop to the bank’s broader Trump relationship. He didn’t. And in 2003, yet another division of ­Deutsche Bank, one that focused on helping companies raise money by selling stocks and bonds to investors, agreed to work with Trump. The point man on this venture was Richard Byrne — another Merrill veteran who had also been involved in the Taj Mahal debacle. (Byrne helped sell the ill-­fated Taj bonds to investors.) Now Trump hired Byrne’s group at ­Deutsche Bank to issue bonds for his Trump Hotels & Casino Resorts company.

It would have been reasonable to expect that Waugh would have warned Byrne about the recently rejected $500 million loan, but that never happened. So Byrne pressed on, organizing a “road show” for Trump to meet with and try to win over big institutional investors. When that didn’t drum up the desired money, Byrne’s salesmen worked the phones, casting a wider net for more clients and managing to sell more than $400 million of junk bonds (albeit at a high interest rate that reflected investors’ fears that Trump might default). Trump repaid the ­Deutsche Bank team with a weekend trip to his Mar-­a-­Lago resort in Palm Beach, Fla.

The following year, with his casinos on the rocks, Trump’s company stopped paying interest on the bonds and filed for bankruptcy protection. (“I don’t think it’s a failure,” Trump said. “It’s a success.”) ­Deutsche Bank’s clients, the ones who had recently bought the junk bonds, suffered painful losses. In the future, Trump would effectively be off-­limits for Byrne’s division.

But that still didn’t render Trump persona non grata for the entire bank. This was a product, at least in part, of ­Deutsche Bank’s internal dysfunction. Many big companies are compartmentalized, but ­Deutsche Bank took it to an extreme. It wasn’t just that rival divisions of the bank didn’t communicate well; they often battled against one another to win clients and amass power for their leaders within the organization — a poisonous atmosphere that Trump, perhaps inadvertently, managed to exploit.

Trump soon went back to the commercial real estate group, asking for a loan to build a 92-­story skyscraper in Chicago. He reportedly seduced the ­Deutsche bankers with flights on the same 727 that had recently taken Byrne’s salesmen to Florida. He invited Kennedy and his colleagues to Trump Tower and lavished them with praise. He explained that his daughter Ivanka would be in charge of the Chicago development — that’s how important this project was to the Trump Organization.

Just as Waugh hadn’t warned Byrne about the rejected Trump loan, now Byrne didn’t warn Kennedy and the other commercial real estate bankers about his own recent Trump experience. “We just looked the other way,” a former executive explains. “That was the ­Deutsche Bank culture.”

Image
Trump Hotels & Casino Resorts, Atlantic City. Bond offering of more than $400 million (2003).
Trump Hotels & Casino Resorts, Atlantic City. Bond offering of more than $400 million (2003).Credit...Michael Ein/The Press of Atlantic City, via Associated Press
In 2002, Joe Ackermann was named chief executive of ­Deutsche Bank. A reserve officer in the Swiss military and a number cruncher with a nearly photographic memory, Ackermann also had a notoriously short fuse. His staff was terrified of disappointing him.

Shortly after taking charge, he made a bold and fateful public promise: The bank would become roughly six times as profitable within a couple of years. Senior executives from that era say that in order to achieve Ackermann’s objective, they quickly shifted the priorities inside the bank. The overriding mission became to make as much money as possible, as quickly as possible, with scant attention to the long-term consequences. A saying took hold among the bank’s leaders: “The current quarter is the most important quarter we’re ever going to have.” Shareholders now became the bank’s most important constituency.

On the surface, Ackermann’s strategy seemed successful. The bank met his lofty profitability targets on schedule, in part by increasingly using its own money — as opposed to customers’ — to shoot for the moon with speculative market bets, a strategy known as proprietary trading. The bank’s shares climbed higher. The company was showered with industry awards.

Years later, it would become clear how ­Deutsche Bank pulled this off: by taking dangerous shortcuts and, at times, breaking the law. In its zeal to goose its profitability metrics, the bank neglected to invest enough in internal technology systems or top-tier compliance and risk-­management staffs. When employees cooked up schemes to launder money, violate sanctions, manipulate markets, avoid taxes or mislead customers, there were few internal checks and balances to detect or stop such behavior. In the rare instances when employees voiced concerns, they were often ignored and were sometimes punished for getting in the way of the boss’s all-­important profitability directive.

Trump was among the beneficiaries of these shortcuts. Before making the Chicago loan, ­Deutsche Bank conducted an informal audit of his ­finances. Trump had declared to the bank that he was worth more than $3 billion, but ­Deutsche Bank concluded that the real number was closer to $788 million — a quarter of what Trump said it was. For most banks, this would have been disqualifying, but ­Deutsche Bank was undeterred. Executives were so eager for growth and big deals that they managed to look past the obvious red flags. In February 2005, ­Deutsche Bank agreed to lend him $640 million for the Chicago project.

Around this time, and out of public view, ­Deutsche Bank provided a series of other services to Trump that haven’t been previously reported. It created numerous “special purpose vehicles” to make it easier for him quietly and inexpensively to acquire international properties for himself and his companies. Trump at the time was trying to diversify his portfolio of assets outside the United States, striking deals to buy properties outright and simply slapping his name on other people’s buildings. Thanks to the magic of financial engineering, the vehicles ­Deutsche Bank created enabled Trump to do real estate deals in places like Eastern Europe and South America without putting any of his own money on the line. Not only was he taking out loans to finance the acquisitions, but he was also using other people’s money to cover the small “equity” portion of the purchases. ­Deutsche Bank would sell investors the rights to whatever revenue the projects generated in the future in exchange for the investors’ — or the bank’s — covering the money Trump owed upfront for the acquisitions. As a result, ­Deutsche Bank and investors bore the risk, over many years, that the Trump projects would not bring in as much money as expected.

This sort of structure was hardly unheard-­of for real estate developers. “It’s a well-­seasoned financing technique,” Mark Ritter, a ­Deutsche Bank executive who was familiar with the transactions at the time, told me. It was an easy way for the bank to generate a steady stream of fees from deep-­pocketed customers. But it increased the bank’s already heavy exposure to Trump — and helped the mogul strike under-­the-­radar deals in far-flung locales, including some that were popular destinations for people looking to hide assets.

­Deutsche Bank also helped Trump find buyers for condos in his properties, according to people familiar with the arrangements. When he partnered in 2006 with a Los Angeles developer to build a Trump-­branded resort in Hawaii, ­Deutsche Bank organized get-­togethers in London and elsewhere to connect Trump and his partners with wealthy clients — including some from Russia — who used anonymous shell companies to buy units in the Waikiki hotel complex.

Some senior executives discussed the potential pitfalls of the Trump relationship. It wasn’t only the not-­insignificant risk that Trump would default on loans. The bankers also talked about Trump’s well-­documented ties to the organized-­crime world — he had done business with people in or affiliated with the mob in Atlantic City and New York — and the possibility that his real estate projects were laundromats for illicit funds from countries like Russia, where oligarchs were trying to get money out of the country. “Everyone in the real estate business was involved in ‘flight capital,’ ” a top executive told me. But the loans looked profitable, the relationship felt valuable and the concerns went unheeded.


When the 2008 financial crisis arrived, Trump still owed $334 million on ­Deutsche Bank’s loan for his Chicago skyscraper. With the economy sinking, nobody was buying the luxury apartments in the building. As the loan’s due date approached that November, Trump filed a lawsuit, trying to void the loan because of the financial crisis, which he accused ­Deutsche Bank of having helped ignite. He sought damages of $3 billion. ­Deutsche Bank filed its own suit, seeking to recoup the $40 million portion of the loan that Trump had personally guaranteed back in 2005. Shortly after the suit was filed, Trump bumped into Justin Kennedy. “Nothing personal,” Trump said. Kennedy replied that there were no hard feelings: Business was business. (Kennedy left the bank at the end of 2009.) But the lawsuit did what the defaults somehow had not: It prompted Deutsche Bank to wash its hands of Donald Trump. In the future, he wouldn’t even be permitted to enter the bank’s golf tournament.

Relative to many of its ruined rivals, ­Deutsche Bank enjoyed a “good” financial crisis. It lost billions, but it had also placed market bets that anticipated the housing crisis, and the resulting profits largely made up for other losses. It was one of the few major international banks that seemed strong enough to avoid a direct government bailout, and many investors were pacified by the knowledge that if things got really dicey, the German government would come to the rescue.

For a brief spell, ­Deutsche Bank was the toast of the financial world. Within a few years, though, it had become one of the industry’s leading problem cases. The crisis — and the waves of new regulations that came afterward — fundamentally changed Wall Street. ­Deutsche Bank’s business model had hinged on making enormous wagers with borrowed money; in essence, the one-time icon of German sobriety had become a giant casino. Now this proprietary trading was outlawed in the United States. Regulators around the world — deeply suspicious of the sort of adrenaline-­crazed, rule-­bending tactics that had come to define ­Deutsche Bank — also pushed banks to lessen their reliance on borrowed funds.

Cocky from their performance during the crisis, ­Deutsche Bank executives initially refused to do so. Nor did they use this moment of relative strength to rid the bank of the mountains of unwanted assets — in particular, trillions of dollars’ worth of derivatives that had the potential to saddle the bank with enormous losses — that were polluting its balance sheet.

One of the few concessions the bank did make to the new era was to start looking for safer ways to earn money. One was private banking: providing personalized services to the richest of the American rich. To differentiate its then-­sleepy private-­banking division from the competition, ­Deutsche Bank planned to work with customers who were untouchable for rival banks and to do deals that were too risky or too complicated for others to stomach — a variation on the strategy that Offit and Kennedy’s squad had deployed a decade earlier when trying to get the commercial real estate business off the ground. And no one was more central to that project than a woman named Rosemary Vrablic.

Vrablic grew up in the Bronx and then the New York City suburb of Scarsdale and started out as a bank teller before eventually landing a job analyzing proposed loans. In 1989, a headhunter recruited her for a job in Citicorp’s private-­banking arm. Citi was widening its suite of offerings to such clients, including by making loans to finance their big real estate projects. She quickly took advantage of this new lending service to become one of New York’s leading bankers to the superrich, first at Citi and then at Bank of America. Vrablic specialized in dealing with difficult men. “They’re successful, and they’ve earned their money by being tough,” she explained in an interview years later. “So I don’t have a problem with tough.” One of her youngest clients was Jared Kushner, who was taking over his family’s real estate company.

In 2006, Vrablic met Tom Bowers, who had joined ­Deutsche Bank the year before with a mandate to help the German bank make a name for itself among ultrawealthy Americans. Vrablic, who was 46 at the time, soon agreed to join ­Deutsche Bank, with a guaranteed salary and bonus of at least $3 million a year. She started bringing in tens of millions of dollars in annual revenue for the bank. Bowers told me she was by far the top producer in the bank’s New York offices.

The litigation between Trump and ­Deutsche Bank over the loan for his Chicago skyscraper was settled in 2010, with the bank agreeing to give Trump two years to make good on his obligations, including the $40 million that he had personally guaranteed. And if he wanted to keep expanding his empire, he would need to identify a new source of credit. The trouble, as ever, was that serious banks wouldn’t get anywhere near him. Even ­Deutsche Bank, it seemed, was now off-­limits after the Chicago fight.

In 2011, Jared Kushner invited Vrablic to visit his father-­in-­law at Trump Tower. Trump explained his situation to her and then popped the big question: Would Vrablic’s division consider lending him $40 or $50 million, with Chicago’s Trump International Hotel & Tower as collateral? That would allow him to repay what he still personally owed ­to Deutsche Bank. The whole idea — that one arm of ­the bank would lend money for the purpose of paying off defaulted debts owed to another part of the company — seemed crazy, but Vrablic was excited by the prospect of landing a major deal with a major new client. She took the proposal to Bowers, who agreed that it was worth considering.

Image
Trump International Hotel & Tower, Chicago: $640 million loan (2005).
Trump International Hotel & Tower, Chicago: $640 million loan (2005).Credit...John Walton/PA Images/Getty Images
A small team sifted through Trump’s personal and corporate financial records and tax returns. The first thing the bankers noticed was that Trump was, once again, vastly overstating his fortune, assigning absurdly high valuations to his real estate assets. In one especially egregious case, he claimed that a property he bought in Westchester County for about $7 million was now worth $291 million. The bank ended up reducing the assets’ values by as much as 70 percent.

The funny thing was that Trump’s underlying finances weren’t all that bad. He had limited debt, at least compared with his fellow real estate magnates, and cash was pouring in, apparently from TV royalties and licensing deals he had struck to put his name on properties he didn’t own. Making the transaction more palatable for ­Deutsche Bank, Trump was willing to personally guarantee the loan, meaning that ­Deutsche Bank in theory could seize his assets if he didn’t pay it back. (The fact that a similar, albeit smaller, personal guarantee hadn’t prevented him from defaulting on the original Chicago loan did not seem to bother the bank.) Vrablic and Bowers tentatively agreed to lend him $48 million.

When top executives in ­Deutsche Bank’s investment-­banking unit heard that another division was about to rekindle the Trump relationship, they were furious. The head of that unit, Anshu Jain, rang the alarm at a meeting of the bank’s top executives: How could ­Deutsche Bank do business with Trump after he had so publicly burned the bank? What precedent would that set for other would-be deadbeats? If Trump defaulted yet again, how would ­Deutsche Bank explain that to investors and regulators?

Bowers and Vrablic argued that the loan was sound. They grumbled that the investment bankers were just jealous that the private bankers had figured out how to structure a loan with Trump in a way that seemed virtually risk-free for ­Deutsche Bank. The squabble made it to the top of the bank — at which point Ackermann, the chief executive, said he didn’t object to the loan. (Ackermann told me that he doesn’t recall being consulted.)

The bank’s lawyers reviewed the question of whether the company could work with Trump and declared that “this client is cleared.” Stuart Clarke, ­Deutsche Bank’s chief operating officer in the Americas, emailed Bowers a similar message: “There is no objection from the bank to proceed with the client.” Attached to that email was a PDF file containing Trump’s personal and corporate financials, to make clear that everyone who had vetted the proposed transaction was fully aware of the new client’s heavy baggage.

The spigot was open again. When Trump decided to buy the rundown Doral Resort & Spa in Miami for $150 million in 2012, one of his first phone calls was to Rich Byrne, who years earlier helped Trump’s casino company sell junk bonds. Trump’s subsequent default on those bonds ended his relationship with ­Deutsche Bank’s securities unit, which Byrne now ran, but the two men had stayed in touch. Byrne agreed to take a look at the numbers, not bothering to tell Trump that ­Deutsche Bank was unlikely to actually help him with financing.

But the private-­banking division was in the mix. Trump invited Vrablic to Florida to see the property. The day after she got back to New York, she walked into Bowers’s office. “Trump wants to go buy Doral,” she explained, and he wanted ­Deutsche Bank to lend him the money to do it.

For the second time in a matter of weeks, Bowers dispatched a team to study a possible Trump loan. They concluded that, in fact, Trump was getting the resort at a reasonable price. The bank wired $125 million to the Trump Organization. Afterward, Trump called Byrne’s office. “Rich,” he bellowed, “I’m just calling to thank you! I know you must’ve approved it, but Rosemary and her team gave me the money.”

Thinking on his feet and happy to take credit, Byrne pretended that he knew all about the loan. He congratulated Trump and then, as an aside, asked about the interest rate that Vrablic’s squad was charging on the loan. Trump said it was well under 3 percent. Byrne couldn’t believe that ­Deutsche Bank, after everything it had been through with Trump, was now extending him a nine-­figure loan at such a low interest rate.

Image
Trump National Doral Miami, Florida: $125 million loan (2012).
Trump National Doral Miami, Florida: $125 million loan (2012).Credit...Johnny Louis/Film Magic/Getty Images
When Trump bid roughly $1 billion for the Buffalo Bills football team in 2014, Vrablic agreed to back him. (Trump’s bid was rejected, so no loan was required.) A few months later, ­Deutsche Bank lent Trump $170 million to finance the transformation of the Old Post Office building in Washington into a Trump International luxury hotel. Vrablic’s division also lent millions of dollars to other members of the Trump and Kushner families.

Then, in the spring of 2016, Trump came looking for one more loan. It was ostensibly to pay for work on his golf course in Turnberry, Scotland. But Trump was running for president, and it was hard to avoid the suspicion that the loan he was requesting might have something to do with the fact that he was burning through gobs of his own cash on the campaign trail.

Bowers by then had left the bank. (He died in November 2019 in what the Los Angeles County coroner said was a suicide.) Vrablic and her managers said yes to the Scotland loan, but the deal had to be reviewed up the food chain. This would once have been part of Seth Waugh’s job, but he was no longer in charge of ­Deutsche Bank’s American businesses. His successor was a veteran investment banker named Jacques Brand.

Somehow Brand hadn’t realized until now that Trump was one of his company’s most important clients. He was alarmed. He was stunned that the people in his wealth-­management division thought it would be a good idea to lend tens of millions more to Trump — especially right now, in the middle of this violent brawl of a presidential campaign. “Why are we doing business with him?” Brand fumed to his colleagues. “The answer is no.”

Brand didn’t have the power to block the loan unilaterally, but he referred it to a committee charged with safeguarding the bank’s reputation. After hearing a quick summary of the proposed loan, the committee unanimously voted to reject it. “It was an affront to all of our senses,” recalls an executive involved in the deliberations.

Vrablic and her colleagues appealed to another committee, in Frankfurt, which also rejected the proposal. The loan was dead. Nine months later, Trump was elected president. Vrablic received V.I.P. tickets to the inauguration, as well as hard-to-get accommodations in Trump’s newly opened Washington hotel that Deutsche Bank had financed.

In some respects, the association with a polarizing president has been bad for ­Deutsche Bank’s business. Executives told me it has become a bit harder to win assignments from public institutions, like government-­employee pension plans. And ­Deutsche Bank has become an enticing target for ambitious prosecutors and politicians around the world — including Democrats who, after taking control of the House of Representatives last year, swiftly issued subpoenas for the bank’s records on Trump, his family and his companies.

But remarkably, in the final accounting, the Trump relationship may have been an overall positive for both the loyal bank and its prized client. Trump got the money he needed to keep buying and building, which in turn allowed him to maintain the reputation as a respectable businessman that he eventually rode to the White House. ­For its part, Deutsche Bank has pocketed tens of millions of dollars in fees and interest payments. The bank won’t comment on whether Trump is up-to-date with his loan payments, and Vrablic, who remains a bank employee, has declined to publicly discuss her relationship with Trump. But Trump is not known to have defaulted on any of his recent loans or otherwise burdened the bank with large losses; in fact, the overall relationship appears to be profitable.

Most likely, this reflects the bank’s luck, not skill, but some senior executives told me they view the outcome as a vindication of their work for Trump. Their attitude is reminiscent of the complacency that took hold after ­Deutsche Bank skated through the financial crisis, thanks to a combination of good fortune, well-­timed bets and the knowledge of a German government safety net. Some optimistic ­Deutsche Bank officials even believe that because the bank has refused to publicly divulge much about its famous client, it might emerge with an enhanced reputation for probity and discretion — and for getting big things done for desperate customers.

In any case, ­Deutsche Bank, along with the rest of its industry, is benefiting from having Trump in the White House. His administration has been systematically rolling back regulations erected after the financial crisis that were designed to hem in Wall Street and the world’s largest banks. The prohibitions on proprietary trading are loosening. The requirements for how much capital banks need to have are easing. The Consumer Financial Protection Bureau, created to shield borrowers from avaricious lenders, has been neutered. The presumption that the government needs to actively police what banks are doing has been replaced by the empirically dubious assumption that the private sector can mostly look out for itself. This hasn’t solved ­Deutsche Bank’s fundamental problems — its business model is broken, its balance sheet is littered with unwanted assets, its years of misconduct are under government investigation — but it has afforded the bank and the entire industry some much-­welcomed breathing room.

One week after the new president sent his thank-you email to Mike Offit in February 2017, Trump delivered his first address to a joint session of Congress. It was a subdued, disciplined performance in which he hewed, more or less, to the teleprompters and sounded, more or less, like a mainstream politician. After stepping down from the lectern, Trump shook hands with the dignitaries in the audience. In the front row were the Supreme Court justices.

Trump moved down the line until he got to Anthony Kennedy. As Trump pumped the justice’s hand, Kennedy congratulated him on a successful speech. “Very nice, thank you,” Trump replied. “Say hello to your boy,” he added, patting the justice’s arm. “Special guy.”

David Enrich is the finance editor at The Times and the author of the forthcoming book “Dark Towers: Deutsche Bank, Donald Trump, and an Epic Trail of Destruction,” from which his article in this issue is adapted.

A version of this article appears in print on Feb. 9, 2020, Page 35 of the Sunday Magazine with the headline: The Money Behind Trump’s Money 
. Order Reprints | Today’s Paper | Subscribe"
READ 24 COMMENTS